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Abstract 
 
ABSTRACT  
 The mammary gland is a complex tissue which undergoes different morphological changes 
duƌiŶg ǁoŵeŶ’s life. IŶ this thesis, ǁe ǁaŶted to ĐlaƌifǇ the iŶǀolǀeŵeŶt of HDACϳ iŶ the 
regulation of cell proliferation, stemness and neoplastic transformation that occurs in 
mammary epithelial cells, using the MCF10A cell line as a model.  
Histone deacetylases are important modifiers of the epigenetic status in response to 
developmental and environmental cues. The subfamily class IIa HDACs comprises four 
deacetylases (HDAC4, HDAC5, HDAC7 and HDAC9) which are characterized by: poor activity 
against acetyl-lysine, nuclear-cytoplasmic shuttling and the ability to bind MEF2 transcription 
factors. In particular, it was demonstrated that HDAC7 is the most expressed member in 
MCF10A cells, pointing to an important role in the homeostasis of these cells. With the aim 
to investigate the involvement of HDAC7 in mammary epithelial homeostasis, 
morphogenesis and proliferation we knocked out HDAC7 in MCF10A cells with the 
CRISPR/Cas9 system. MCF10A HDAC7-/- cells show an inhibition of cell cycle progression, 
through p21 up regulation. This data confirms the role of HDAC7 as a repressor of the p21 
expression in MCF10A.   
Through microarray analysis we described the gene expression profile of MCF10A lacking 
HDAC7 to reveal the genes directly regulated by the HDAC7 expression.   
Moreover, we investigated the HDAC7 involvement in stem cells growth and maintenance by 
applying the mammosphere assay and FACS analysis. Hence, we propose a double role of 
HDAC7 in the regulation of stemness. First, an intrinsic role of HDAC7 was verified in stem 
cells growth, demonstrating the reduced ability of MCF10A-HDAC7-/- cells to form spheres in 
ultra-low adhesion conditions. This could be explained by a reduced presence of progenitors 
in a population where HDAC7 is absent. Second, an extrinsic role, was proved by the ability 
of HDAC7 to release factors important for the stem cells renewal. In fact, conditioned 
medium by the MCF10A WT cells increases the number of mammospheres, confirming that 
HDAC7 could play a fundamental role in the regulation of factors released by the mammary 
stem cell niches.   
Finally, we also investigated the contribution of HDAC7 in neoplastic transformation. We 
obtained MCF10A HDAC7-/- transformed with the RAS oncogene. We discovered that the 
knock-out of HDAC7 negatively impacts on the RAS transformed phenotype. This observation 
opens new hypothesis on the cooperation between HDAC7 and oncogenes in promoting 
proliferation, invasiveness and altered morphogenic processes. Moreover, we described that 
HDAC7 loss can impact on stemness also in transformed cells. All these findings consolidate a 
pro-oncogenic role of HDAC7 in mammary epithelial cells, promoting the identification of new 
therapeutic strategies to target HDAC7 in breast cancer.  
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Aim of the study 
 
AIM OF THE STUDY  
  
This PhD thesis aims to: a) investigate the role of the neglected epigenetic regulator HDAC7 in 
normal breast development; b) clarify the impact of HDAC7 mutations/amplifications during 
breast cancer progression. We therefore knocked out HDAC7 in normal mammary epithelial 
cells MCF10A using the CRISPR/Cas9 technology. The MCF10A HDAC7-/- cells demonstrate the 
importance of HDAC7 in the cell cycle progression in 2D and 3D cultures. Furthermore, we 
proposed a role of HDAC7 in stem cell self-renewal indicating that HDAC7 is important for the 
growth of progenitor stem cells in a cellular population. Moreover, we hypothesized a new 
role of HDAC7 in stem factors release.   
Finally, we supposed a participation of HDAC7 in neoplastic transformation. To investigate 
this, we transformed MCF10A WT and MCF10A-HDAC7-/- cells with HRAS12V. The obtained 
data show that HDAC7-/- negatively impact on the RAS transformed phenotype of MCF10A 
cells.  Our results justify the opportunities to consider HDAC7 as a new therapeutic target for 
the treatment of many breast related pathologies.   
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1. INTRODUCTION 
 
1.1. Histone Deacetylases (HDACs). 
 
Acetylation is one of the most recurrent post-translational modifications. It regulates several 
cellular functions including the epigenetic state of the chromatin, from which depends DNA 
replication, DNA repair, heterochromatin silencing and gene transcription (Drazic et al., 2016). 
Lysine acetylation is a reversible and tightly regulated histones modification (Martin et al., 
2007). The main actors of this epigenetic regulation are the histone acetyltransferases (HATs) 
and the histone deacetylases (HDACs), which have opposite functions. HDACs are proteins 
involved in the formation of a compact chromatin structure devoted to transcriptional 
repression (Delcuve et al., 2012). 
In mammals, we can count eighteen HDACs, which are divided into four classes based on their 
characteristics and sequences homology (Figure 1). The class I, II and IV are Zn2+-dependent 
proteins instead of the class III groups NAD+- dependent enzymes (Gregoretti et al., 2004). 
Class I: HDAC1, 2, 3 and 8.  
They show a high degree of sequence similarity with the yeast transcriptional regulator Rpd3. 
They are ubiquitously expressed and are located in the nucleus (Martin et al., 2007). 
Class II: HDAC4, 5, 6, 7, 9 and 10. 
They are grouped by their homology with Hda1 (Saccharomyces cerevisiae). The expression of 
these proteins is tissue specific. This class comprise the class IIa formed by HDAC4, 5, 7 and 9 
characterised by nucleus-cytoplasm shuttling, which regulates their activity and the class IIb, 
formed by HDAC6 and 10. The main difference between these two subclasses is that the class 
IIa HDACs, differently form class IIb lacks of the enzymatic activity (Fischle et al., 2002). 
Class III: SIRT1, 2, 3, 4, 5, 6, and 7. 
It is a very different class respect to the other HDACs. They are NAD+- dependent proteins and 
they are homologous to the yeast Sir2. Class III are expressed in different cellular 
compartments including nucleus, cytoplasm and mitochondria (Haigis and Guatente, 2006).  
Class IV: HDAC11  
HDAC11 has a sequence similar to the HDACs of classes I and II. In literature, few information 
about the HDAC11 functions are available. Some data point to a role of HDAC7 in the decision 
between immune activation and immune tolerance (Gao et al., 2002; Delcuve et al., 2012). 
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Figure 1: The HDACs world. 
Representation of the main characteristics of the 18 HDACs found in mammals and indication of 
their sub-cellular localization (from Clocchiatti et al, 2011). 
 
 
 
1.1.1. Class IIa HDACs. 
HDAC 4, 5, 7 and 9 compose the class IIa HDACs subfamily. Since the early 2000s researchers 
have employed a lot of efforts to understand their biological functions (Parra, 2015). The first 
discrepancy between class IIa HDACs and class I, is the presence of a long N-terminal domain 
(absent in class I enzymes) important to regulate HDACs functions (Yang and Gre, 2005). 
Within the N-terminal domain are located some regions necessary for the interaction with 
transcription factors. One of the most described interaction, which takes place at the N-
terminus of the class IIa involves the binding to MEF2 (Myocyte Enhancer Factor) transcription 
factors family members (Miska et al., 1999). In fact, all class IIa HDACs contain the MEF2 
binding domain.  
Class IIa HDACs can shuttle from the nucleus to the cytoplasm, a mechanism important to 
influence their repressive activity on the chromatin. The translocation from the nucleus to the 
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cytoplasm is monitored by serine/threonine phosphorylation and involves highly conserved 
residues present into the N-terminal region (Figure 2). The phosphorylation of these residues 
allows the interaction with the 14-3-3 proteins. 14-3-3 proteins are the main responsible for 
class IIa subcellular localisation (Tzivion et al., 2001). Class IIa HDACs shuttle continuously 
between the nucleus and the cytoplasm. Within the nucleus, they operate as negative 
regulators of gene transcription. When they are into the cytoplasm their repressive influence 
is abrogated. This shuttling is supervised by the NLS and NES sequences. In particular, the 
binding with the 14-3-3 proteins can hide the NLS sequence and can prevent the interaction 
with the importin-α. This stƌategǇ is used ďǇ the Đells to iŵpede the loĐalisatioŶ of Đlass IIa 
HDACs in the nucleus (Grozinger and Schreiber, 2000). The NES sequence is located close to 
the C-terminus. After the conformational change that occurs with the 14-3-3 binding, the NES 
sequence exposition triggers the export of the class IIa HDACs from the nucleus to the 
cytoplasm (Clocchiatti et al., 2011). Experimental evidences show how mutations of serine 
residues into alanine can prevent the nuclear export. Mutations of these fundamental 
residues result in the generation of a super-repressive forms of class IIa HDACs (Clocchiatti et 
al., 2015;  Zhang et al., 2002). 
The main regulators of the class IIa HDACs sub-localisation are phosphatases and kinases. 
Various serine/threonine kinases are involved in the HDACs shuttling. Among them, there are 
the calcium/calmodulin-dependent protein kinase family (CaMK) and in particular CaMK I and 
CaMK IV (McKinsey et al., 2000). Other kinases are involved in the class IIa HDACs localisation.  
These kinases are for example MAPT/tau (MARK1), MARK2 and Serine/threonine-protein 
kinase D1, AMPK (Hanks, 2003). Indeed, two studies proved that protein kinase D1 (PKD1) 
phosphorylates HDAC5 and HDAC7 at their 14-3-3 binding sites (Parra et al., 2005).  
Phosphorylation is not the only post-translational modification investing class IIa HDACs. 
HDAC4 and HDAC7 can be subjected to proteolytic cleavage (Paroni et al., 2004), to 
sumoylation and ubiquitylation (Martin et al., 2007). 
The main discovered functions of this class of proteins occur into the nucleus, where they can 
act on the chromatin. It is important to underline that class IIa HDACs are not able to directly 
bind the DNA. To interact with nucleic acids, they must bind co-factors and transcription 
factors (Madjzadeh et al., 2009). 
To the N-terminus of the class IIa HDACs is associated the ability to inhibit the transcription 
factors activity; this attitude is partially due to the presence of the binding site for the co-
repressor CtBP (C-terminal binding protein) and a coiled coil region rich in glutamine both 
absent in HDAC7 (Martin et al., 2007).  
Even if they are called histone deacetylases, in vertebrate class IIa HDACs lack of a measurable 
enzymatic activity.  Class IIa HDACs are characterised by the presence of a highly conserved 
HDAC domain at the C-teƌŵiŶus, hoǁeǀeƌ this doŵaiŶ is ͞iŶaĐtiǀe͟ oƌ at least inactive on 
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acetyl-lysine (Di Giorgio and Brancolini, 2016). The HDAC domain at the C-terminus is 
important for binding HDAC3. This class I enzyme can provide robust deacetylase activity when 
in complex with others co-repressor SMRT (Silencing mediator for retinoid and thyroid 
receptors) and N-CoR (Nuclear-receptor corepressor 1), which are recruited together with 
HDAC3 by the  HDAC domain of class IIa (Fischle et al., 2002). It has been proposed that class 
IIa HDACs may not be real enzymes but rather, they could act as adaptors for the assembling 
of super-repressors complexes (Parra, 2015). In the HDAC active site, to permit the enzymatic 
activity and the substrate binding, a central motif of conserved residues coordinates a Zn ion 
and is complemented by a second group of highly conserved residues involved in the catalysis. 
Overall the enzymatic domain of class IIa HDACs is similar to the domain of class I HDACs. As 
explained above, with Vertebrates class IIa loose the lysine-deacetylase activity. The molecular 
reason is the substitution of a tyrosine residue that acts as a transition-state stabilizer with a 
histidine, which is shorter and oriented in a different position, thus compromising the 
enzymatic activity (Lahm et al., 2007) (Bradner et al., 2010). 
 
 
Figure 2: Domain organization of classical HDACs from yeast and humans. 
In mammals, class IIa HDAC subfamily includes HDAC4, 5, 7, 9, which are related to yeast Hda1. The 
total number of amino acid residues in each deacetylase is shown on the right. Additional isoforms 
of the deacetylases can arise from alternative splicing; for simplicity, the number of amino acids 
refers to the longest isoform. The homologies of the deacetylase domain with Hda1 
(identity/similarity: 26/57%) are shown. Myocyte enhancer factor-2 (MEF2)-binding motifs are 
depicted as short green cylinders, whereas 14-3-3 binding motifs are shown as short blue cylinders 
labelled with 'S' (for Ser) (from Yang and Seto, 2008). 
 
 
 
1.1.2. MEF2 TFs as class IIa HDACs binding partners. 
Class IIa HDACs reveal their repressive influence on transcription when they reside into the 
nucleus. Class IIa HDACs binding partners, as reported by the literature, include different 
transcription factors (Martin et al., 2007). In this chapter, we will focus the attention on the 
members of the MEF2 family. 
MEF2s are the best characterised partners and this interaction has been studied since 1999 
(Wang et al., 1999). MEF2 proteins are conserved among species. A single MEF2 protein is 
present in Drosophila melanogaster and Caenorhabditis elegans. Instead four members: 
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MEF2-A, -B, -C and –D are present in vertebrates (Miska et al., 1999). The MEF2 factors share 
high homology within the amino-terminal MADS-box and MEF2 domains. MEF2 is a 29 amino 
acids (AA) motif exclusive of the MEF2 factors. These domains are responsible for homo- and 
hetero-dimerization of MEF2 proteins and the interactions with transcriptional co-factors and 
co-regulators, including repressors. Furthermore, the MADS-box/MEF2 domain permit the 
binding to the conserved A-T rich DNA consensus sequences (YTA(A/T)4TAR)  to elicit 
transcriptional activity on gene promoters and enhancers (Black and Olson, 1998; McKinsey 
et al., 2002). If the N-terminal domain is well conserved among the MEF2 members, the 
carboxyl-terminal regions are highly divergent. The C-terminal is represented by the 
transcription activation domains (TADs) and by the NLS sequence. Moreover this region is 
susceptible to splicing events (Potthoff and Olson, 2007;Lu et al., 2000). 
It is well known that through an autoregulatory loop, MEF2 family members can maintain their 
own expression (Ramakrishnan et al., 2002; Cripps et al., 2004). 
Initially discovered as key regulators of muscle differentiation, Myocyte enhancer factor-2 
family members promote the expression of target genes involved in different biological 
functions. It is important to mention that their function is not just related to muscle tissue. 
For example, MEF2C is important also for neural differentiation,as confirmed by the 
generation of specific Mef2C KO mice, which evidenced less mature neurons (Li et al., 2008). 
MEF2s are also involved in the hematopoietic cells differentiation and MEF2A, C, and D 
regulate apoptosis and EMT processes (Canté-Barrett et al., 2013; Pon and Marra, 2016; 
Zhuang et al., 2013). The importance of these proteins is proved by the generation of KO mice. 
Mef2A and Mef2C null mice exhibited respectively, neonatal death, because of lethal cardiac 
arrhythmias (80% of newborns) and embryonic lethality at E10.5, due to cardiovascular 
defects (Lin et al., 1997; Canté-Barrett et al., 2013; Pon and Marra, 2016; Zhuang et al., 2013). 
Curiously, Mef2B or Mef2D KO mice survive and do not present abnormalities. An absence of 
overt phenotype that can be justified with the compensation phenomenon from others MEF2 
members (Pon and Marra, 2016). 
There are evidences that MEF2s regulate cell cycle progression by activating the transcription 
of CDKN1A. The CDK inhibitor p21 (CDKN1A) is a well-known negative regulator of cell cycle 
progression, under the control of multiple signals (Besson et al., 2008; Karimian et al., 2016). 
It was demonstrated that MEF2D down-regulation was coupled with the reduction of CDKN1A 
levels, an increase in DNA synthesis and augmented cell proliferation. mRNA levels of MEF2 
target genes and of CDKN1A were reduced in cells with impaired MEF2D expression (Di Giorgio 
et al., 2015). In particular, ChIP experiments demonstrated that MEF2D binds the CDKN1A 
promoter at +2.1 and +1.5 kb from the TSS (Clocchiatti et al., 2015).  
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1.1.3. HDAC7. 
Identification of histone deacetylase 7 (HDAC7) dates back to 2000 (Kao et al., 2000). The 
carboxy-terminal of the HDAC7 shows high homology with the other class IIa HDACs and the 
N-terminus show similarities with HDAC4, 5 and hMITR. It can bind and repress MEF2 
transcription, however it lacks the Glu rich domain, presents in HDAC4/5/9. The longest 
HDAC7 isoform contains 952 residues and it is encoded by HDAC7 gene, located into the 
chromosome 12q13.1 minus strand. The HDAC7 promoter has the minimal PDGF-BB-
responsive element, which contains one binding site for the transcription factor Sp1. Mutation 
of the Sp1 binding site abolished PDGF-BB-induced HDAC7 activity (Zhang et al., 2010). In silico 
predictions confirmed byEncode data suggest that HDAC7 expression could be regulated by 
some proto-oncogenes acting as transcription factors on the HDAC7 promoter. Among these 
proto-oncogenes  JUN, FOS and MYC can be found (Di Giorgio and Brancolini, 2016). 
 
Regulation of HDAC7 activity 
Like others class IIa HDACs, HDAC7 can shuttle in and out from the nucleus by the 14-3-3 
binding. Unlike to HDAC4, 5 and 9, HDAC7 has four serine residues (positions 155, 181, 321, 
446) that through phosphorylation, allow the binding with 14-3-3 proteins (Grozinger and 
Schreiber, 2000;Dequiedt et al., 2005). As a consequence the HDAC7 quadruple mutant, in 
which the four serine residues are replaced by alanine residues (S155A, S181A, S321A, S446A), 
is not efficiently exported from the nucleus to the cytoplasm, confirming the importance of 
these serines into the nucleo-cytoplasm shuttling (Clocchiatti et al., 2015; Dequiedt et al., 
2003).  
Different kinases are responsible for these phosphorylations. An example is represented the 
PKD1 that acts on HDAC7, mediating the repression of Nur77 expression (Dequiedt et al., 
2005). Moreover, HDAC7 phosphorylation by PKD1 is supervised by VEGF concentration, thus 
linking HDAC7 activities to RTK signalling (Chang et al., 2008).  
Additional 14-3-3 binding sites or phosphorylation-independent mechanisms that mediate the 
export of HDAC7 could exist as the cytoplasmic accumulation of HDAC7 phospho-mutants is 
some circumstances is reported(Gao et al., 2006).  
On the contrary phosphatases are involved in the nuclear accumulation of HDAC7. One of 
them is PP2A that directly dephosphorylates the 14-3-3 binding sites in HDAC7, thus 
preventing the association of 14-3-3 proteins (Martin et al., 2008).  
In thymocytes, where HDAC7 is highly expressed, the myosin phosphatase complex (PP1β and 
MYPT1) dephosphorylates HDAC7 and permits its translocation into the nucleus. This 
regulation is mandatory for the inhibition of the apoptosis in CD4+/CD8+ cells (Parra et al., 
2007). Also the Rho-Kinase (ROCK) is involved in this pathway. In fact, ROCK acts through 
phosphorylation of the Myosin Phosphatase, specifically targeting subunit 1 (MYPT1). ROCK 
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activity leads to the inhibition of the myosin light chain phosphatase (MLCP). As we already 
mentioned, MYPT1 and the catalytic subunit of MLCP (PP1) interact specifically with HDAC7 
dephosphorylating it. Hence, ROCK, thought re-localising HDAC7, induces the down-regulation 
of NR4A1 expression, a member of the nuclear orphan receptors. The final output is the 
promotion of the T cell tolerance by the induction of apoptosis in thymocytes (Kasler et al., 
2011). Compagnucci et al., demonstrated that phosphorylation levels of MYPT1 increase in 
parallel with ROCK activity. Hence, as a consequence, HDAC7 phosphorylation also increases. 
Moreover, they demonstrated that low levels of ROCK activity correspond to an increase in 
the MYPT1/MLCP-dependent de-phosphorylation of HDAC7, thus promoting its nuclear 
export (Compagnucci et al., 2015).  
Until now, two different splicing variants of HDAC7 have been characterised. The most 
common spliced isoform is made up of 25 exons (HDAC7s), whereas the second one is an 
isoform that conserves the first intron after the first ATG (HDAC7u) (Di Giorgio and Brancolini, 
2016). A manuscript reported that this splicing event is fundamental in smooth muscle cells 
(SMC) proliferation both in mice and humans. HDAC7 is normally maintained as an unspliced 
isoform in the cytoplasm, where it binds β-catenin to mantain SMCs in a quiescent state. PDGF 
(Platelet-derived growth factor) stimulation triggers HDAC7 splicing, which allows β-catenin 
release. In this way β-catenin translocates into the nucleus and binds TCF transcription factors 
to activate the expression of genes required for entry the S phase of the cell cycle (Zhou et al., 
2011).  
miRNAs also play a relevant role in the regulation of the HDACs activities. In particular, two 
miRNAs are able to target HDAC7: miR140-5p and miR34. 
Over-expression of miR140-5p reduces HDAC7 expression and the expression of others target 
genes in Cal27 cells (human tongue squamous carcinoma cell line). This regulation causes a 
reduction in cell migration (Kai et al., 2014). In breast cancer, miR34 has key roles favouring 
cell-survival and therapy resistance. Among genes regulated by this miRNA there are HDAC1 
and HDAC7 (Wu et al., 2014). 
Finally, HDAC7 is also subjected to proteolytic cleavage. For example, HDAC7 undergoes 
proteolysis during caspase-8 mediated apoptosis. In CD4/CD8 positive thymocytes HDAC7 is 
cleaved by caspase-8. This processing influences HDAC7 subcellular localisation and consents 
the establishing of the Nur77-dependent gene expression response (Scott et al., 2008).  
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HDAC7 tissue specific expression 
  
 
  
 
Figure 2: HDAC7 expression in Human tissues. 
The image represents the expression of HDAC7 in human tissue. It is possible to appreciate the high 
levels of HDAC7 in the endocrine tissues and in the immune system (from proteinatlas.org) 
 
As the other class IIa HDACs, HDAC7 shows a heterogeneous tissue expression (Figure 2). 
HDAC7 is highly expressed in heart, thymus, lung, CD4+/CD8+ thymocytes and in vascular 
endothelium (Clocchiatti et al., 2011). Importantly, HDAC7 is more abundant in human thymus 
compared to HDAC4 and HDAC5. Interestingly, HDAC7 expression is modulated during 
thymocytes maturation. In primary human thymocytes, sorted by flow cytometry based on 
the differentiation markers CD3, CD4 and CD8, HDAC7 is abundant. On the other hand, low 
levels of HDAC7 mRNA were observed in immature triple-negative thymocytes (TN, CD3-CD4-
CD8-). HDAC7 expression was highly and transiently increased during the CD4+CD8+ DP stage 
and returned to lower levels in mature Single Positive T cells (SP4 or SP8). Regulation of HDAC7 
expression is important to modulate MEF2D transcription, which is able to induce Nur77 
expression and thus triggering apoptosis. For this reason, during the maturation of Double 
Positive T cells, signals emanating from the TCR lead to the displacement of HDAC7 from MEF2 
and its re-localization into the cytoplasm. The displacement of HDAC7 from the Nur77 
promoter and other promoters, regulated in a similar manner, leads to the MEF2-dependent 
activation of Nur77 and apoptosis (Verdin et al., 2004). HDAC7 has a role also in the 
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development of B cells. In B cells progenitors HDAC7 interacts with MEF2C and represses a set 
of genes involved in the establishment of the B cells identity and development (Azagra et al., 
2016). 
The embryonic lethality of HDAC7 null-mice arises from defects in the adhesion of endothelial 
cells. This deficit causes a defective angiogenesis and impairs vessels integrity. Indeed, HDAC7 
mutant embryos show an increasing expression of the MMP10 in the vascular endothelium, 
and a consequent down regulation of the tissue inhibitor of metalloproteinase 1 (TIMP1). This 
observation confirms that HDAC7 inhibits MMP10 transcription through the association with 
MEF2C, an activator of MMP10 expression (Chang et al., 2006).  
VEGF plays a pivotal effect in angiogenesis by regulating the proliferation, migration, and 
survival of endothelial cells. As we already mentioned, VEGF can control HDAC7 
phosphorylation via PKD. It was demonstrated that HDAC7 regulates VEGF-Induced expression 
of RCAN2 and Nur77 genes, which are implicated in angiogenesis (Wang et al., 2008). 
Furthermore, HDAC7 can sustain cell motility and angiogenesis, by regulating  PDGF-B/PDGFR-
β genes expression (Mottet et al., 2007). 
A single manuscript reported that in different cell lines and in particular in prostate cancer cell 
lines, HDAC7 is sequestered into the mitochondria where it is processed at the N-terminal 
domain. Afteƌ the ͞ŵitoĐhoŶdƌial Đleaǀage͟ the ƌesultiŶg HDACϳ is a pƌoteiŶ of ϴϬ KDa that is 
located within the inner membrane space and released into the cytoplasm after pro-apoptotic 
signals (Bakin and Jung, 2004). 
A negative impact of HDAC7 was proposed for cartilage formation and regeneration. A study 
reported that HDAC7 binds β-catenin in proliferating chondrocytes inhibiting its function. 
During chondrocytes maturation, HDAC7 is degraded by the ubiquitin-proteasome system 
into the cytoplasm. HDAC7 degradation increases β-catenin activity and enhances post-natal 
chondrocyte proliferation (Bradley et al., 2015).  
Not only in chondrocytes but also in osteoblasts HDAC7 is important for maturation. Jensen 
and co-authors described, by applying a RNAi approach, a repressive activity of HDAC7 on 
RUNX2 until the moment when osteoblasts undergo maturation. During the osteoblast 
differentiation process, BMP2 acts as a signal to trigger the osteoblast maturation. BMP2 
transiently impacts on HDAC7 nuclear localization and permits to switch-on RUNX2-
dependent gene expression (Jensen et al., 2008). 
Finally, class IIa HDACs are historically known to negatively regulate myogenesis by inhibiting 
MEF2. When HDAC7 translocates into the cytoplasm, muscle differentiation starts through 
MEF2 activation (Dressel et al., 2001)(Lu et al., 2000). 
 
 
 
Introduction  
  
14  
HDAC7 in breast 
In our laboratory, we are investigating the importance of HDAC7 in breast tissue. The 
morphogenetic processes that control the mammary gland development is very complex and 
not completely defined.  To study the influence of the MEF2-HDACs axis on mammary 
epithelial morphogenesis and maintenance, we initially compared expressed sequence tag 
(EST) profiles for class IIa HDACs, MEF2A, MEF2C and MEF2D within different tissues. We 
discovered that in breast tissue, MEF2A, MEF2D and HDAC7 are the most expressed proteins 
(Clocchiatti et al., 2015). 
Gene Set Enrichment Analysis (GSEA), using a signature of putative MEF2-target genes, 
suggested that MEF2-dependent transcription was positively modulated during MCF10A 
acinar morphogenesis. With the consciousness that expression of HDAC7 in this cell line could 
be related to some mechanism of mammary gland development, we decided to investigate 
the HDAC7 role in breast using the MCF10A cell line as experimental model. Experimental 
evidences demonstrated that HDAC7 changed its expression during acini formation. At day 4, 
HDAC7 is abundantly expressed but at the day sixteen its expression is reduced by post-
transcriptional mechanisms. This phenomenon seems to be independent from proteasome-
mediated degradation or lysosome- and autophagy-mediated degradation (Clocchiatti et al, 
2015).  
During the acinar morphogenesis, the regulation of the cell cycle exit is very important. Class 
IIa HDACs are involved in the regulation of transcription of CDKN1A (p21), a negative regulator 
of the cell cycle progression (Wilson et al., 2008). With ChIP experiments, we explained that 
HDAC7 binds the p21 promoter preferentially to the region containing the MEF2-binding site 
at +1.5 kb from the transcription start site (TSS). 
 We generated MCF10A cells expressing a conditionally super-repressive form of HDAC7 
(HDAC7/SA-ER), fused to the ligand binding domain of the oestrogen receptor (Dequiedt et 
al., 2003). Upon treatment with 4-OHT, this chimera accumulates into the nucleus and 
represses MEF2-dependent transcription. When grown in 3D conditions MCF10A expressing 
HDAC7/SA-ER formed acini bigger than the control at all time points analysed. The increasing 
in size depends on an increase in the number of nuclei per acinus. These data indicate that 
HDAC7 can stimulate epithelial cell proliferation (Clocchiatti et al., 2015).  
 
 
 
1.1.4. Class IIa HDAC7 in cancer: an oncogene or a tumour-suppressor? 
To date, the role of HDAC7 in the neoplastic transformation is controversial. There are 
evidences claiming for a tumour suppressive role and others that demonstrate an oncogenic 
activity for HDAC7.  
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We already discussed about the importance of HDAC7 in endothelial cells (EC) and the relation 
between HDAC7 and β-catenin. Margariti et al., in 2010, demonstrated that the knockdown 
of HDAC7 promotes the endothelial cells proliferation causing hypertrophy (Margariti et al., 
2010).  
Recent results in Pro-B acute lymphoblastic leukaemia (pro-B-ALL) and Burkitt lymphoma, 
evidenced a down-regulation of HDAC7 in these two cancer types. In addition, an inducible 
expression of HDAC7 in lymphoma and leukaemia cell lines reduced their viability (Barneda-
Zahonero et al., 2015). Although the anti-proliferative contribution of HDAC7 in this study is 
unclear, taking together these data shed light on new highly specific therapies for the 
treatment of pro-B-ALL and B-cell lymphoma (Barneda-Zahonero et al., 2015). 
Despite these results, the idea that class IIa HDACs are aberrantly overexpressed in cancer, is 
still prevalent. A genomic screening conducted on 154 glioma patients, demonstrated a strong 
positive correlation between STAT3 down-regulation and HDAC7 expression, strictly related 
to a poor clinical outcome. In glioma, it has been demonstrated that HDAC7 has a strong role 
in angiogenic pathways activation. In fact, STAT3 can induce anti-angiogenic genes when 
HDAC7 is not present. Considering that glioblastoma cells are addicted to angiogenesis, a 
down-regulation of HDAC7 should inhibit the uptake of oxygen and nutrients, required for the 
cancer growth. Unfortunately, to date, no specific inhibitors does exist for HDAC7, making its 
targeting extremely difficult in glioblastoma (Peixoto et al., 2016). 
The crucial role of HDAC7 in cancer proliferation was also confirmed in HeLa cells. In this cell 
line, HDAC7 activates the c-Myc transcription. When HDAC7 in knocked down, there is a 
support of the expression of some regulators of the cell cycle such as p21 and p27. ChIP assay 
was carried out to better understand the histone acetylation of c-Myc gene. As expected the 
HDAC7 silencing promotes a strong decrease of histone H3/H4 acetylation compared with the 
control (Zhu et al., 2011). 
In pancreatic adenocarcinoma (PA), HDAC7 has a crucial role in proliferation. It has been 
demonstrated by a screening on PA patients, that HDAC7 is overexpressed and its expression 
is linked to a poor clinical outcome (Ouaïssi et al., 2014).   
Furthermore, the oncogenic activity of HDAC7 was also revealed in breast cancer. There are 
evidences that HDAC7 is highly expressed in the triple negative breast cancer cells, with a peak 
in the BRCA1-mutated HCC1937 cells (Clocchiatti et al., 2013) . In oestrogen receptor (ER)-
positive tumours cells, the HDACs-MEF2 axis is compromised by on over expression of class 
IIa HDACs causing a strong repression of putative MEF2-target genes (Clocchiatti et al., 2015).  
All these evidences could be explained with a dual role of HDAC7, related to a specific 
tissue/lineage context. Understanding these specificities will help researchers to better define 
the influence of HDAC7 in tumour progression.  
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1.1.5. Class IIa HDACs in stemness. 
In literature, evidences suggest that class IIa HDACs could be involved in different stem 
pathways. It is well demonstrated that the activation of the epithelial/mesenchymal transition 
(EMT), in non-transformed epithelial cells, promotes stemness (Fabregat et al., 2016).  
Not surprisingly epigenetic changes are critical for the EMT and it is possible to impede the 
EMT plasticity using the HDACs inhibitors. In 2015, Ruscetti published that the treatment with 
the histone deacetylase inhibitor LBH589 inhibit EMT plasticity and stemness activities in 
prostatic cancer cells (Ruscetti et al., 2015, 2016).  
It is also true that the available information about the involvement of HDACs in stemness is 
still not well defined and controversial. As a matter of fact, in 2010 it was published that 
OCT3/4, a crucial transcription factors in stem cells re-programming, binds the first intron of 
HDAC4 gene, interfering with splicing maturation. This interaction down-regulates HDAC4 
transcription in embryonic stem cells (Addis et al., 2010).  
On the contrary, it was demonstrated that, in glioblastoma (GLB), HDAC4 could have a crucial 
role in regulating stem potential. Importantly, the presence of GLB cancer stem cells can 
induce radio-resistance in patients treated with radiotherapy. Researchers investigated the 
ability of GLB stem-like cells (GSLC) and adherent not stem-like cells, to form CD133-and 
Nestin-positive neurospheres after HDAC4 or HDAC6 silencing. They confirmed that HDAC4 or 
HDAC6 knockdown counteracts the ability to generate neurospheres. Moreover, in GSLCs 
obtained from neurospheres, the levels of nuclear HDAC4 and HDAC6 proteins were 
augmented. These results suggest that HDAC4 and 6 could be involved in stem pathways 
within these cells (Marampon et al., 2017).  
Recent discoveries demonstrated an important role of HDAC7 in stem regulation in breast and 
ovarian tissue. A correlation between high HDAC7 protein expression and CSC markers in 
breast and ovarian cancer cell lines was observed. To better understand the role of HDAC7 in 
maintaining cancer stem phenotype, the authors knocked-down the expression of HDAC7. The 
resulting data proved that HDAC7 depletion decreases CSC markers expression and inhibits 
mammospheres formation. These data were confirmed by HDAC7 over-expression in which 
an up regulation of CSC markers was evident. These findings indicate that HDAC7 is necessary 
and sufficient to augment the CSC phenotype in breast and ovarian cancer cell lines (Witt et 
al., 2017). 
 
 
 
 
Introduction  
  
17  
1.2.  Human mammary gland. 
 
1.2.1. Breast anatomy. 
 
 
Figure 4: Human breast. 
Representation of the anatomy of human breast with the indication of the single component (from 
Wikipedia). 
 
Breast in humans is an organ that plays a fundamental role in lactation (Figure 4). Breast is 
present in both males and females, but they become more prominent in females during 
puberty. Among the mammalian species, breasts number depends from the average number 
newborns at birth (http://teachmeanatomy.info/thorax/organs/breasts/). 
Anatomically, breast presents at the centre the nipples, which are surrounded by a pigmented 
area of skin called areolae. The areolae contain little glands called Montgomery glands, 
responsible of the lipoid fluid secretion. This secretion acts as a protective lubricant, important 
during breastfeeding and its smell attracts for the infant.  
The breast contains the mammary glands, the key structures responsible in all the functions 
in which this organ is involved. 
A mature mammary gland is composed by alveoli and ducts (Macias and Hinck, 2013) 
(Gudjonsson et al., 2009). Alveoli gather together to develop structures known as lobules (Fig. 
4). Each lobule is connected with the lactiferous ducts. Ducts are structures that connect the 
lobules with the nipples (Love and Barsky, 2004). Under the oxytocin stimulation, the ducts 
through contraction support the milk flow from alveolar units to the nipples (Haaksma et al., 
2011).  
Humans normally have two mammary glands, one in each breast. Every mammary gland 
consists of 10/20 simple lobules and each lobule is formed by 10/100 alveoli. All these 
structures are sustained by the stroma, connective tissue principally composed by collagen 
and elastin (Campbell and Watson, 2009). In addition to the connective tissue, breasts are 
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supported by the presence of adipose tissue that surrounds the mammary gland. 
Furthermore, in breast there is a diffuse presence of blood and lymphatic vessels. Both type 
of vessels play a key role in cancer because of the spreading of cancer cells from breast to 
lymph nodes and other tissues, supporting the formation of metastasis. 
 
 
 
1.2.2. Mammary gland cellular composition. 
As we described above, the ductal network terminates in lobular units commonly known as 
the terminal duct lobular units (TDLUs) (Yang et al., 2012). The TDLU structure represents the 
basic mammary gland unit.  
The entire mammary gland is constituted by two main mammary epithelial cell (MEC) 
subtypes: an external layer of basal MECs (myoepithelial cells) and an inner layer of luminal 
MECs (Loeffler and Roeder, 2002).  
Myoepithelial (or basal) cells are present on the perimeter of the lobules and of the ducts, 
where they establish contacts with the extracellular matrix, by hemi-desmosomes and to the 
adjacent luminal epithelial cells to desmosomes (Gusterson et al., 1982). The myoepithelial 
layer that surrounds the ducts, represented by spindle-shaped cells, is a continuous layer 
(Gudjonsson et al., 2009). On the contrary, the myoepithelial cells surrounding the lobular 
structures, create an irregular layer, permitting the interaction between the luminal epithelial 
cells and the basement membrane (Glukhova et al., 1995).  
There are a set of cytokeratins expressed by myoepithelial cells such as CK5, 14 and 17, which 
are crucial for the mammary cytoarchitecture (Dairkee and Heid, 1993). The myoepithelial cell 
cytoplasm is filled with actin and myosin, which are responsible of the contractile phenotype 
mediated by oxytocin stimuli during lactation (Murrell, 1995). The contractile phenotype is 
suppoƌted ďǇ the eǆpƌessioŶ of the α-sŵooth ŵusĐle aĐtiŶ ;α-sm actin) and of the heavy chain-
myosin (hc-myosin) (Lazard et al., 1993). Beside the contractile properties, this cell layer has 
the peculiarity to contribute to the basement membrane production, through the secretion 
of fibronectin, collagen IV and laminins (Gudjonsson et al., 2009). The strong connection 
between the extracellular matrix and myoepithelial cells is guaƌaŶtee ďǇ the eǆpƌessioŶ of βϰ 
aŶd αϭ iŶtegƌiŶs (Lambert et al., 2012).  
Strong evidences demonstrate that, among the myoepithelial cells there are cells that lack 
typical characteristics of the myoepithelial lineage, which can be considered progenitor cells. 
(Oakes et al., 2014) (Joshi et al., 2012). 
A single layer of luminal epithelial cells delimits the lumen of lobules and ducts. The luminal 
lineage can be further subdivided into ductal and alveolar luminal cells (Visvader and Stingl, 
2014). To support the critical changes occurring during puberty and pregnancy, the epithelium 
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of the mammary gland must be extremely dynamic. This requirement can explain the 
heterogeneous composition of this tissue, made by early stage stem cells, progenitors and 
differentiated cells (Twigger et al., 2015).  
The alveolar epithelial cells are in prevalence ER+/-,CD29low, CD49f+, CD24+, CD61- and express 
CK7 and CK19 (Joshi et al., 2012; Visvader and Stingl, 2014). Alveolar epithelial cells are the 
only responsible of the milk production and secretion (Taylor-Papadimitriou et al., 1989). 
Alveolar cells start to proliferate during late pregnancy to support the final development of 
the alveolar structures (Kobayashi et al., 2016). Milk production by alveolar MECs is elicited 
by prolactin and glucocorticoids stimulation at birth (Houdebine et al., 1985).  
The ductal epithelial differentiated cells could be ER- or ER+, EpCam+, CD49f+, MUCI+. The main 
keratins expressed in this layer are the CK7, 8, 18, 19 (Taylor-Papadimitriou et al., 1989). 
Microscopically, the luminal layer is formed by cuboidal epithelial cells bound together by the 
tight junctions (TJ), principally composed by one or more types of Claudins (Cldns) (Sasaki et 
al., 2003). Claudins supervise changes in TJ permeability that occurs during parturition and 
lactation (Kobayashi et al., 2016). The tight junctions are the principal responsible of the 
mammary ductal barrier and the main regulators of the polarity of the luminal epithelial cells. 
The polarization of these cells explains why the myoepithelial side of the epithelial cells have 
different functions compared with the apical membrane (membrane side of the cell exposed 
to the alveolar lumen) implicating also a polarization of the organelles of the cells (Roignot et 
al., 2013). 
 
 
 
 
 
 
 
 
1.2.3. Breast cancer. 
Indeed, breast cancer is a highly heterogeneous disease and can be classified into different 
categories using specific parameters:  
 
Histopathological:  The histopathological classification of breast carcinoma is based on the specific 
morphological features of different tumours. The most common classification divides the breast 
carcinoma in 
1) The Ductal Carcinoma In Situ (DCIS) is one of the most common type, which means 
that the original site of the disease is within the ducts. DCIS most often occurs at a 
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single site. In 90% of the cases, DCIS is not palpable and it is discovered through 
screening mammography. DCIS is more commonly diagnosed in women with the 
incidence rising steadily after age 40 (Winchester et al., 1972). 
2) The Lobular Carcinoma in situ (LCIS) is an indolent, non-invasive breast lesion 
characterized by abnormal changes in the cells that compose the milk-producing 
lobules. LCIS is a marker indicating that a woman is at increased risk of developing 
breast cancer. However, most women with LCIS will never develop breast cancer 
(Makki, 2015).  
3) The Invasive/Infiltrating Ductal Carcinoma (IDC) is the most common subtype (70–80% 
of all invasive lesions) (Malhotra et al., 2010). Here cancer cells have penetrated the 
basement membrane that separates the ductal epithelium from the underlying tissue 
and invaded the surrounding breast tissue. Cells may then metastasize in other tissues 
through the bloodstream or lymphatic system (Malhotra et al., 2010).  
4) The Invasive Lobular carcinoma (ILC) is relatively uncommon, comprising about 5-15% 
of invasive breast cancers. The prognosis is similar to the invasive ductal carcinoma, 
but often is more favourable. ILC metastasize later than invasive ductal carcinoma. 
Compared with invasive ductal carcinoma, patients with ILC are more often prone to 
bilateral disease. Because of its infiltrative growth pattern, a diagnosis of ILC may be 
arduous, particularly with dense breast tissue (Guiu et al., 2014; Keshtgar et al., 2010). 
Grade: Pathologists also classify breast cancer by grade. The grade is defined according to the 
appearance of the tissue after biopsy. A lower grade usually means that the cancer grows 
slower and is less likely to metastasize, whereas a higher grade refers to faster cancer growth 
with more probability of spreading. Grade 1 means that the cells look most like normal cells 
and they are well differentiated, while grade 2 means moderately differentiated. Grade 3 
refers to poorly differentiated cells that waste their tissue-related characteristics and are 
identified by accelerated proliferation (Zhang et al., 2012). 
Stage: Stage 0 is referred to a not invasive cancer. At stage 1 patients usually have invasive 
breast cancer, smaller than two centimetres.  Spreading to the lymph nodes is observed but 
not outside the breast tissue. Stage 2 is when the tumour has spread to the auxiliary lymph 
nodes, which can be from two to five centimetres and remain localized or measure 0.2 to two 
millimetres of metastasis. Stage 3 describes a more aggressive form of invasive breast cancer. 
Stage 4 indicates the that the cancer has spread to other organs of the body such as the lungs, 
the liver, distant lymph nodes, skin or bones. This is the stage with less favourable prognosis 
(Zhang et al., 2012). 
Molecular classification: This classification is one of the most important because of the gene 
expression component of the cancer cells permits targeted therapy to patients. Gene 
expression profile studies classify breast cancer as: basal-like, HER2+, normal breast like, 
luminal subtype A, luminal subtype B and claudin low. These breast cancer types are divergent 
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because of their patterns of gene expression, clinical features, response to treatment and 
prognosis.  
Basal-like (BLBC): They represent the greatest challenge because of the clinically aggressive 
nature and poorly characterized molecular pathogenesis. BLBC group triple negative breast 
cancer marked by the lack of the oestrogen (ER) and progesterone (PR) receptors, and the 
absence of HER2 overexpression (Schnitt, 2010). These peculiarities confer to the cancer cells 
resistance to specific disease-oriented therapies such as: tamoxifen and aromatase inhibitors 
or trastuzumab. Generally, cells from basal-like breast cancer evidence expression of 
cytokeratins  5/6, epidermal growth factor receptor (EGFR), and other basal-related genes 
(Toft and Cryns, 2011). In addition, many sporadic basal-like breast cancers show BRCA1 
dysfunction (Schnitt, 2010). 
HER2+: Amplification of the HER2 gene and/or overexpression of the encoded protein have 
been found in up to 25% to 30% of human breast cancers and have been shown to be 
associated with poor prognosis. HER2-positive breast cancer are diagnosed by 
immunohistochemistry (IHC), which identifies overexpression of HER2 and fluorescence in situ 
hybridization (FISH), which identifies amplification of the HER2 gene (Rena Callahan, 2011). 
An improvement of patieŶts’ outcome has been obtained in the recent years by applying 
specific therapies such as the monoclonal antibody trastuzumab and the small molecule 
tyrosine kinase inhibitor lapatinib.  
Luminal A and Luminal B: Luminal A tumours express high levels of ER and/or PR and low levels 
of proliferation related genes. Generally, luminal A tumours have low histological grade and 
have a good outcome, whereas luminal B cancers have more often higher histological grade, 
higher proliferation rates and a significantly worse prognosis compared luminal A 
counterparts (Weigelt et al.). In some cases, Luminal B overexpress HER2 (Schnitt, 2010). 
Normal breast-like: Unlike the other four breast cancer subtypes, with well recognizable 
molecule characteristic pattern, the normal-like subtype is still undefined (Weigelt et al., 
2010). This cancer expresses adipose and non-epithelial genes and shares high basal like gene 
expression patterns. Normal-like tumours have an intermediate prognosis (Toft and Cryns, 
2011). 
Claudin-low: Less information are available on this breast cancer subtype, in particular 
concerning the clinical treatment and biological changes. These weaknesses depend on its 
recent discovery/classification. The claudin-low subgroup comprises tumours which evidence 
tƌaŶsĐƌiptoŵiĐ featuƌes suggestiǀe of a ͞ĐaŶĐeƌ steŵ Đell-like͟ pheŶotǇpe (Hennessy et al., 
2010; Herschkowitz et al., 2007). Claudin-low cells are ER-, PR- and HER2-. 
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1.3. Stem cells. 
  
1.3.1. Mammary stem cells. 
 
 
Figure 5: Mammary stem cells. 
Hypothetical model of human mammary epithelial stem cell hierarchy and differentiation. (A) 
Mammary stem cells and their progenitors. A bipotential stem cell gives rise to luminal epithelial 
and myoepithelial cells, but the intermediary steps and their regulation are largely unknown. (B) 
Schematic picture of a normal terminal duct lobular unit with the putative location of the various 
stem and differentiated cells indicated (from Polyak 2007) 
 
Currently scientists strongly affirm the presence of human mammary stem cells (MaCSs) 
(Figure 5). To support the development, remodelling and differentiation in response to the 
hormonal signals, the breast tissue must be sustained by the presence of undifferentiated 
cells. Hence, MaCSs must be considered as multipotent stem cells. These cells have the ability 
to both self-renew and generate daughter cells that can differentiate in several lineages within 
the breast tissue.  
Stem cells localisation in the mammary gland is still unclear but there are evidences that these 
cells are mostly located in ducts and alveolar regions. Accordingly, mammary epithelial 
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fragments extracted from different areas of the mammary gland can give rise to new ductal 
trees (Fridriksdottir, Agla J.R., et al., 2011).  
Different studies tried to prove the mammary stem cells ability to recreate breast tissues. 
Tissue fragments or dissociated MECs have been introduced into the mouse mammary fat 
pads of immunocompromised mice but these experiments resulted unsuccessful, presumably 
because of the lack of an adequate stromal environment (Kuperwasser et al., 2004). These 
unsuccessful experiments unveiled the key role played by stromal cells in stem cells growth 
and maintenance. Stem cells are important but their properties will be useless without the 
stroma-derived signals released by the mammary stem cell niche. The exact nature of these 
stromal released factors has not yet fully elucidated. In order to form a functional ductal tree, 
stroma-derived signals should govern both symmetrical and asymmetrical division of the stem 
cells. It is important to underline that steroid hormones play a pivotal role in directing the fate 
of the stem cell, probably by acting on the stem cell niche (Fridriksdottir, Agla J.R., et al., 2011). 
Kuperwasser published in 2004 a work in which they demonstrated that the fat pad injection 
with human mammary stromal fibroblasts, supported the creation of a humanized stromal 
environment. The highly activated microenvironment created by these cells was characterized 
by remodelling of the extracellular matrix proteins of the stroma, including increased collagen 
synthesis and activation of TGF-β sigŶalliŶg (Kuperwasser et al., 2004). Moreover, in the same 
study they demonstrated that this chimeric fat pad is essential for the ductal and acinar 
structures formation after the human MEC organoids injection. These data confirmed the 
importance of the environment where the MaCSs are located.  
More recently, a new model described how fibroblasts and putative mammary stem cells 
recapitulate the hierarchal nature of the normal human mammary gland. The used model took 
advantage from engraftments in a collagen plug under the murine kidney capsule (Eirew et 
al., 2008). 
To isolate cells with stem properties, scientists have identified some special molecular 
markers. In particular cell surface markers have been useful to both identify and characterize 
mammary stem cells and Cancer Stem Cells (CSCs).   
The list of common stem markers includes: 
CD44: is a member of a large family of cell adhesion molecules, responsible for the 
communication and adhesion among adjacent cells and between cell and extracellular matrix 
(ECM). The CD44 gene contains 20 exons, which encode ~20 CD44 isoforms (Fox et al., 1994). 
The non-variant standard isoform, denoted as CD44s, is the smallest and most widely 
expressed isoform. It is expressed at the surface of many cell types (Louderbough et al., 2011). 
The longest isoform CD44v (250 KDa) is a well-known marker for normal and cancer stem cells 
(Witt et al., 2017). Importantly, the expression of specific CD44 isoforms has been detected in 
advanced stages of cancer. In particular, the overexpression of the variant isoform CD44v6 
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has been detected in cervical, colorectal and pancreatic carcinomas and correlates with poor 
prognosis and metastatic potential (Morath et al., 2016).  
CD49f/α-6 integrin: ITGA6 is considered a stem marker thanks to studies realized on the 
epidermal stem cells (Li et al., 1998). In 2006, two groups isolated mouse mammary stem cells 
in virtu of the surface profile marked by CD24- and CD49f+ (Stingl et al., 2006)(Shackleton et 
al., 2006). Cells which expressed CD4f in combination with CD44 generate higher number of 
mammospheres in culture and shown tumorigenesis in vivo (Duru et al., 2016). 
ALDH1: Aldehyde dehydrogenase 1 (ALDH1) is an intracellular enzyme, frequently selected as 
a marker of both normal and cancer stem cells (Ginestier et al., 2007). Many studies described 
the expression of this marker in normal and cancer stem cells. Among the many different 
ALDH1 isoforms, ALDH1A3 is related to stemness (Qu et al., 2015) and tumorigenesis (Marcato 
et al., 2011) 
CD24: is a glycosylphosphatidylinositol-linked cell membrane adhesion protein expressed in a 
variety of malignant tumors including ovarian cancer, breast cancer and lung carcinoma (Lim 
et al., 2014). Its contribution to stemness is still unclear. Cells with stem features show low 
CD24 expression in combination with CD44 high expression (Qu et al., 2015). CD44+/CD24−/low 
breast cancer cells have significant tumorigenic properties and have been identified as a 
cancer stem cell (CSC) population. Conversely in 2010 Gao et al., (Gao et al., 2010) described 
how CD24+ ovarian cancer stem cells are enriched for cells at the S phase compared with 
CD24− population. Moreover, they described that CD24+ cells preferentially expressed genes, 
which have an essential role in self-renewal, proliferative capacity and fate determination. 
Overall these studies suggest that stem cell-like characteristics of CD24+ cells are mediated by 
multiple signalling pathways, for example, Wnt signaling and Notch signaling pathways. Well 
known signalling systems involved in the regulation of stem cell function and niche stem cell 
interactions (Gao et al., 2010). 
 
 
 
1.3.2. Breast cancer stem cells. 
Tumours are characterised by a strong cellular heterogeneity. A key question that researchers 
try to answer is:  do all the neoplastic cells sustain cancer? or is this feature just restricted to 
a small population of cells? 
In 2003 Dick proposed the cancer stem cells (CSC) theory. This theory could explain why in 
solid tumours, only a small proportion of the neoplastic cells are able to form colonies in vitro 
and why a huge number of cells must be transplanted in mice to permit the rising of the 
neoplastic mass (Dick et al., 2003). Tumours can be heterogeneous tissues governed by a 
hierarchical organisation. Within the tumour, there is a rare population of cells, called the 
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tumour initiating cells (T-IC) which are defined as cells with self-renewal ability and tumour-
initiating capacity (Zhou et al., 2009).  In breast cancer for example, a primitive breast cancer-
initiating cell (BrCa-IC) grows and thanks to the self-renewal can maintains the BrCa-IC 
population and the tumour growth. The same cells, on the other side, can differentiate giving 
rise to the breast cancer cells that lost the ability to sustain the tumour. Some of these 
͞diffeƌeŶtiated͟ Đells ĐaŶ still ďe ĐoŶsideƌed pƌogeŶitoƌ Đells, ďut theǇ haǀe lost the aďilitǇ to 
sustain the tumour after transplantation (Dick, 2003). 
Evidences supporting the CSC theory in breast cancer were published by Al-Hajj in 2003 (Al-
Hajj et al., 2003). This work described how in breast cancer, just a distinct population of cells 
can form tumours in mice. These cells are detectable by the presence of specific markers. For 
example, CD44+/high/CD24-/low cells from patients with neoplasia, exhibited properties of 
cancer stem cells (Al-Hajj et al., 2003).  
Within a tissue, a CSC can be created de novo. This process is characterised by the Epithelial 
Mesenchymal Transition (EMT), a process that can mark cancer development but also normal 
morphogenesis of the mammary gland (Nelson et al., 2010).  
EMT in cultured cancer cells is characterized by the loss of epithelial markers (E-cadherin and 
epithelial cytokines) and the gain of mesenchymal markers like SNAIL, TWIST, Vimentin and 
many others (Turley et al., 2008). These changes in gene expression promote the disruption 
of the epithelial polarity and establish a mesenchymal phenotype (Cabrera, 2015). EMT results 
in an increased migratory and invasive potential and in the acquisition of a cell-surface marker 
profile characteristic of breast CSCs (CD44+/high/CD24-/low). The EM transition promotes, in this 
way, self-renewal properties, and most importantly, tumor-initiating ability to the cells 
(Marjanovic et al., 2013) 
Unfortunately, breast cancer stem cells and normal breast stem cells have very similar 
characteristics and for this reason it is very difficult to recognise them in a heterogeneous 
population (Britton et al., 2011).  
As discussed above certain markers can be used to recognize breast cancer stem cells. CD44 
splice variants seem to have an important role in tumorigenesis. In fact, some studies 
suggested that variant isoforms expression is linked to an increased metastatic behaviour. For 
example, transfection of CD44 variants into a non-metastatic rat pancreatic carcinoma cell 
line, caused a metastatic potential in these cells (Louderbough and Schroeder, 2011). 
Beside CD44 and CD24 other markers can be used to identify cancer stem cells in a population. 
ALDH is a common marker for both normal and malignant stem and progenitor cells. Analysing 
the expression of ALDH1 in 577 human breast carcinomas, it was proved that the expression 
of this stem cell marker is a powerful predictor of poor clinical outcome (Ginestier et al., 2007). 
However, the definition of markers and their use could be not simple to identify a very 
heterogeneous population like breast cancer stem cells. In fact, a recent paper described the 
Introduction  
  
26  
lack of correlation of stem cells markers in BCSCs. They examined through 
immunohistochemistry the expression of different cancer stem markers and they affirm that 
within the same population, the expression of each marker is different. For this reason, each 
marker identifies a unique sub-population of cancer cells, rather than identifying the same 
population of cells (Liu et al., 2014). 
In 2012 a manuscript described two markers that could help to find cancer stem cells in a 
population. Among ten markers tested in different human breast cancer cell lines, CD14 and 
CD90 resulted the most promising. CD90 could be a potential marker of breast CSCs, since 
CD90+ cells represented more than 90% of cells in the Hs578-T cell line, directly correlating 
with their high tumorigenicity and metastatic potential. On the contrary, the CD14 marker is 
expressed in a non-tumorigenic cell line. In fact, CD14 is higher than 60% in the non-
tumorigenic MCF10-A cell line and less than 15% in the Hs578-T tumorigenic and metastatic 
cell line (Lobba et al., 2012). These data further stress the need of finding real cancer stem 
markers in order to bypass the heterogeneity within the cancer stem cells.  
 
 
 
1.4. The stem cells niche. 
 
 
 
 
Figure 6: Mammary stem cell niche. 
Model of the breast stem cell niche. Key populations of the mammary stem cell niche include 
mammary stem cells (MSCs), mesenchymal stem cells, endothelial stem cells (ESCs), bi-potent 
progenitor (BPP), luminal progenitor (LP), myoepithelial progenitor (MEP), myoepithelial cells (MCs), 
luminal epithelial cells (LCs), and stromal cells (from Tieu et a., 2012). 
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The stem niche can be defined as the microenvironment where the adult stem cells are 
maintained (Figure 6). Niches are sites where external signals can influence the stem cells 
behaviour to permit a quiescent state, the self-renewal or the differentiation. 
 First  demonstration and characterization of niche components was conducted in simplest 
model organisms such as Drosophila melanogaster and Caenorhabditis elegans gonads (Xie 
and Spradling, 1998).  
Curiously, in niches from different tissues and organisms, some conserved components can 
be found. Stromal cells and the extracellular matrix are important players of the niche. Stromal 
cells are close to the stem cells and secrete factors important for stemness properties, 
whereas the ECM acts as an anchor for the epithelial cells. Furthermore, the stem niche is 
supported by blood vessels, which are important for the nutritional support and help the 
recruitment of circulating stem cells from and to niches (Jones and Wagers, 2008). It is also 
true that progenitor cells are important in the niche mainteŶaŶĐe. The ͞daughteƌ pƌogeŶitoƌ 
Đells͟ seŶd foƌǁaƌd sigŶals to the pƌogeŶǇ, iŶstƌuŵeŶtal to pƌeǀeŶt theiƌ diffeƌeŶtiatioŶ. 
Pardo-Saganta demonstrated that basal stem/progenitor cells regulate the maintenance of 
their own progeny (Pardo-Saganta et al., 2015).  
 
 
 
1.4.1. Molecular pathway associated with niche functions. 
Soluble factors and molecules present in the microenvironment are the most important 
components of stem niches, required to keep active pathways for stem cells maintenance. 
DiffeƌeŶt pathǁaǇs aƌe eŶgaged ǁithiŶ the ŶiĐhes iŶĐludiŶg WŶt/β-catenin, Notch, 
Angiopoietin-1 (Ang-1) bone morphogenetic protein (BMP) and several growth factors, such 
as fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), insulin growth 
factor (IGF), transforming growth factor-alpha (TGF-alpha) and platelet derived growth factor 
(PDGF) (Ferraro et al., 2010). 
IGFs 
Among the molecules present in the niche there are the small polypeptides (~7 KDa) known 
as Insulin Growth Factors (IGF-1 and IGF-2). The expression of IGFs is under the control of the 
growth hormone. In fact, experimental evidences demonstrate that in the stromal cells the 
growth hormone (GH) binds the GH receptor and triggers IGF-1 mRNA expression (Kleinberg, 
1997). IGFs action takes place thanks to the engagement of the IGF-1R and the IGF-2R (IGF-2 
specific receptor) which are tyrosine kinase receptors.  
Through different signalling pathways, IGF-1/2R activity is transduced in changes of gene 
expression aimed to promote survival, self-renewal, and differentiation of MSCs (Youssef et 
al., 2017).  
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IGFBPs 
To modify the activity of the free IGF-1 ligand there is a class of IGF-binding proteins (IGFBPs, 
1-6). Under physiological conditions, IGFs bind IGFBPs with higher affinity than they bind IGF-
1R. IGFs and IGFBPs proteins interact through non-covalent binding that resulted important 
for the protection against their degradation.  An increase in their half-life facilitates the 
delivery to different tissues (Youssef et al., 2017). The IGFBPs family is composed by six 
members, which are characterised by conserved N and C-terminal domains and variables 
regions in the middle of the proteins. The N-terminal domain is formed by 80-93 aa and is 
highly conserved among the IGFBPs. Particularly, at the N-terminus lies  a conserved motif 
(GCGCCxxC), presents in all the IGFBPs, with the exception of IGFBP-6. The real function of this 
motif is still unclear but researchers suppose that this motif is fundamental for the IGFs 
binding. Although IGFBP-6 lacks this motif, it shows high binding affinity with the IGFs. The C-
terminus domain of the IGFBPs, is well conserved like the N- terminal domain and is involved 
in the IGFBPs binding between the cell surface and the extracellular matrix (Hwa et al., 1999). 
The IGFBP (1-6) possess a strong affinity for IGF-1 and IGF-2, but how this class of proteins can 
release the IGFs? Different strategies are employed to free IGFs. IGFBPs can be subjected of 
proteolysis, alteration in phosphorylation status and conformational changes (Hwa et al., 
1999). 
Among the IGFBPs there is another class of protein the IGFBP-rPs (1-9), well known for their 
less affinity for the IGFs than the IGFBPs. For example, IGFBP-7 (Mac25 or IGFBP-rP1) has 
binding sites for IGF-1, insulin, VEGFA and activin A and has been described as BMP antagonist. 
Down regulation of IGFBP7 was associated with unfavourable outcome in breast, lung and 
pancreatic cancer, demonstrating a correlation between the expression of these proteins and 
cancer (Bolomsky et al., 2015). 
BMP 
The bone morphogenic protein belongs to the TGF-β supeƌfaŵilǇ aŶd has a stƌoŶg ƌole iŶ the 
stem regulation. There are more than twenty BMPs, which act through two types of receptors: 
type 1 and 2.  
There are two well-known pathways within BMPs are involved, the first acts through the 
receptor type I which phosphorylate Smad1, Smad5, or Smad8 (R-Smad). Two phosphorylated 
R-Smads form a hetero-trimeric complex with a common Smad4 (coSmad). This complex 
translocates into the nucleus and cooperates with other transcription factors to modulate 
target gene expression. The second pathway involves the X-linked inhibitor of apoptosis (XIAP) 
which, after BMP binding can activate the JNK and NF-kB pathways (Zhang and Li, 2005). 
Among the BMPs, BMP-2 and BMP-4 are key regulators of the cell fate and differentiation of 
the human mammary epithelial stem cells. In particular it was demonstrate that BMP-4 
Introduction  
  
29  
prevents the lineage differentiation of the MCF10A cells, by promoting stemness (Clément et 
al., 2017). 
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2. MATERIALS AND METHODS  
  
Cell cultures and reagents.    
   
Human normal immortalized epithelial breast cells (MCF-10A), MCF-10A HRasG12V, MCF10A 
MEFϮD VPϭϲ aŶd MCFϭϬA MEFϮD ∆DBD ǁeƌe ŵaiŶtaiŶed iŶ Haŵ’s FϭϮ/DMEM ϭ:ϭ ŵediuŵ 
(Sigma-Aldrich) supplemented with 5% horse serum (Euroclone), penicillin (100U/ml), 
streptomycin (100µg/ml), L-glutamine (2mM) (Lonza), insulin (0,01mg/ml), hydrocortisone 
(500ng/ml), cholera toxin (100ng/ml) (Sigma-Aldrich), and epithelial growth factor (EGF) 
(20ng/ml) (Peprotech). HEK-293T aŶd AMPHO Đells ǁeƌe gƌoǁŶ iŶ DulďeĐĐo’s ŵodified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), L-glutamine (2mM), 
penicillin (100U/ml), and streptomycin (100µg/ml) (Lonza). Cells expressing inducible forms 
of HDAC7 were grown in complete F12/DMEM medium without phenol red (Sigma-Aldrich) 
and with 5% charcoal stripped horse serum. 4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich) was 
used at 1µM.   
  
Three-dimensional morphogenetic assay.    
   
The 3D morphogenetic assays were conducted as described (Debnath et al., 2002). To obtain 
acini, cells (3x10^4) were plated in a thick layer of ~1-2mm of laminin-rich extra-cellular matrix 
(Cultrex-Sigma-Aldrich). Cultrex was overlaid with cells grown in DMEM F12 containing 5ng/ml 
EGF along with 2% v/v Cultrex.  
Cells were maintained at 37ºC and 5% CO2 and the culture medium was changed every four 
days. Images of acini were collected by using a Leica AF 6000LX microscope. Instead, confocal 
images with a Leica confocal microscopy SP equipped with a 488 ʄ Aƌ laseƌ aŶd a ϱϰϯ to ϲϯϯʄ 
HeNe laser. Acinar area measurements were determined using ImageJ software.   
  
Mammosphere assay  
  
Maŵŵospheƌes ǁeƌe gƌoǁŶ iŶ Maŵŵospheƌes Mediuŵ ŵade up Haŵ’s FϭϮ/DMEM ϭ:ϭ 
medium (Sigma-Aldrich) serum free, supplemented with B27 (1X) (Gibco) and EGF (20ng/ml) 
;PepƌoteĐhͿ seeded oŶ Ultƌa Loǁ AttaĐhŵeŶt ŵultiǁells ;CoƌŶiŶgͿ. Afteƌ ϯϬ’ of tƌǇpsiŶ, ϭϬϬϬ 
cells were seeded in 24 ULA-MW and cultivate at 37ºC and 5% CO2 for ten days, adding new 
medium every two days (Shaw et al., 2012). For the BMP4 (Thermo fisher) and IGF-1 
(Peprotech) treatments, MCF10A cells were pre-treated at a concentration of 15 ng/ml for 2 
days, then single cells were seeded onto 24-well ultra-low attachment plates at limiting 
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dilution (1000 cells/24-plate well) in medium, as described previously. Spheres larger 50 µM 
were counted.  
Conditioned medium was obtained by seeding MCF10A CTRL and MCF10A HDAC7-/- in 
complete Mammospheres Medium for 2 days in tissue culture plates (Sarstedt) (1.25^105 
cells/ml). After 2 days the medium was collected, filtered and diluted 1:1 with fresh 
Mammospheres Medium and used for the MCF10A CTRL and MCF10A HDAC7-/- seeding.  
Images of mammospheres were collected by using a Leica AF 6000LX microscope.  
Mammospheres area was determined using Imagej image analysis software.  
  
MCF10A HDAC7-/- achievement  
  
MCF10A HDAC7-/- cells were obtained using the CRISPR/Cas9 technology. With the aim of 
obtaining different KO clones, three guides were designed targeting different exons. To do 
this ǁe used the ďioiŶfoƌŵatiĐs tool ͞CRI“PR desigŶ ͞aǀailaďle fƌoŵ http://crispr.mit.edu/ to 
design three gRNAs.  
gRNA eǆoŶ ϯ: ϱ’CACCGAGCGCTCGGTGGAGCCCATG ϯ’ 
gRNA eǆoŶ ϰ: ϱ’CACCGCCGATGCCCGAGTTGCAGG ϯ’ 
gRNA eǆoŶ ϱ: ϱ’ CACCGGGTCAAGCAGAAGCTACGG ϯ’  
The three guides pair immediately before the PAM sequence (NGG). gRNAs were clone into 
the lentiviral plasmid pLentiV2 which bring the Cas9 sequence and the gene for the puromycin 
resistance. CTRL cells were infected with the pLentiV2 lacking the guide. Immediately after 
the infection cells were selected by puromycin. Monoclonal cultures were obtained seeding 
single cell in 96 multiwells. Clones were screened by immunoblot. KO clones for HDAC7 were 
further validated by Sanger sequencing.  
  
Proliferation assay  
  
MCF10A CTRL and HDAC7 KO 1*104 cells/ml were seeded in a 12 multiwell plates. Cells were 
trypsinized and counted with a solution 0.1% Tripan blue. All experiments were done in 
triplicate.  
  
Immunofluorescence and immunoblotting   
  
Cells were fixed with 3% paraformaldehyde and permeabilized with 0.1% Triton X-100. The 
secondary antibodies were Alexa Fluor 488-, 546-, or 633-conjugated anti-mouse and 
antirabbit (Molecular Probes). Actin was labeled with phalloidin-AF546 (Molecular Probes) 
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or phalloidin- ATTO 665 (Sigma-Aldrich). Cells were imaged with a Leica confocal microscopy 
“P eƋuipped ǁith a ϰϴϴ ʄ Aƌ laseƌ aŶd a ϱϰϯ to ϲϯϯ ʄ HeNe laseƌ.   
Cell lysates after SDS-PAGE and immunoblotting were incubated with primary antibodies. 
Secondary antibodies were obtained from Sigma-Aldrich, and blots were developed with  
Super Signal West Dura (Pierce). For antibody stripping, blots were incubated for 30 min at 
60°C in stripping solution coŶtaiŶiŶg ϭϬϬ ŵM β-mercaptoethanol   
  
Antibody used 
 
The following primary antibodies were used: MEF2D (BD Bioscience), MEF2A (Santa Cruz  
Biotechnology), p53 and pERK (Cell Signaling Technology), p21, ACTIN and RACK-1 
(SigmaAldrich), RAS (Abcam), HDAC4 (Paroni et al., 2004), HDAC5 (Clocchiatti et al., 2015), 
mouse antiBrdU (Sigma-Aldrich) and secondary antibodies were obtained from Sigma-
Aldrich. For HDAC7 antibody production, rabbits were immunized with recombinant 
histidine-tagged HDAC7 fragment 261-522 purified from Escherichia coli. For anti-HDAC7 
antibody purification HDAC7 was fused to glutathione S-transferase (GST) and cross-linked 
to glutathione-Sepharose as described previously (Paroni et al., 2001).  
  
Plasmid construction, transfection, retroviral and lentiviral infection  
  
To generate pWZL-Hygro-HDAC7 WT-ER, an EcoRI fragment of HDAC7 WT was cloned into 
pWZL-Hygro-ER. MCF-10A cells expressing HDAC7 WT-ER, RAS-V12G, MEF2-VP16 and 
MEF2ΔDBD transgenes were generated by retroviral infection as described previously 
(Cernotta et al., 2011). 293T AMPHO packaging cells were transfected 24h after plating by 
calcium-phosphate precipitation and incubate at 32°C. After 48h the virus-containing medium 
was filtered and added to target cells.   
gRNAs were cloned in pLENTiv2 vector. MCF10A was infected with lentiviral particles. 293T 
packaging cells were transfected 24h after plating by calcium-phosphate precipitation and 
incubate at 37°C. After 24h the virus-containing medium was filtered and added to target cells.  
  
RNA extraction and quantitative qRT-PCR.  
  
Cells were lysed using Tri-ReageŶt ;MoleĐulaƌ ReseaƌĐh CeŶteƌͿ. ϭ ʅg of total RNA ǁas 
retrotranscribed by using 100U of Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). Quantitative reverse transcription-PCR (qRT-PCR) analyses were performed using 
Bio-Rad CFX96 and SYBR Green technology. The data were analyzed by use of a comparative 
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threshold cycle method using HPRT (hypoxanthine phosphoribosyltransferase) as normalizer 
gene. All reactions were done in triplicate  
 
   RNA expression array and data analysis.  
  
Total RNA was isolated with RNeasy (Qiagen). Samples were profiled using Illumina 
HumanHT12 expression Beadchip v 4.0. The BeadChips were scanned with the Illumina's 
Beadarray system scanner (Illumina, San Diego, CA, USA). Each array on the BeadChip targets 
> 47,000 probes derived from the National Center for Biotechnology Information Reference 
Sequence (NCBI) RefSeq Release 38 (November 7, 2009) and other sources, using 3-µm beads 
bearing covalently attached 50-base oligonucleotide probes. The raw data images were 
imported into Illumina Genome Studio, which generated an average intensity of each probe 
for each sample. The Bead Studio output was then processed with the lumi package (Du et al., 
2008) in Bioconductor using the variance stabilizing transform and quantile normalization.  
Fold-change and P-values for each probe set were calculated using a moderated t-statistic in 
the limma package (Ritchie et al., 2015), with the variance estimate being adjusted by 
incorporating global variation measures for the complete set of probes on the array. The 
Pvalue data were then corrected for multiple hypotheses testing using the Benjamini and 
Hochberg. Differentially expressed genes (DEGs) were selected based on fold change >1.5 and 
<-1.5 fold and P values <0.05.  
Gene set enrichment analysis (GSEA) (Subramanian et al., 2005) was used to investigate 
putative statistical association between genes modulated by HDAC7 and genes perturbed by 
other signal transduction pathways.  
  
FACS analysis and BrdU assay  
  
For cell cycle FACS aŶalǇsis, Đells ǁeƌe fiǆed ǁith ethaŶol ;O/NͿ, tƌeated ǁith ϭϬʅg RŶase A 
(Applichem Lifescience) and stained with 10µg propidium iodide (Sigma-Aldrich). Data were 
analyzed with Flowing Software (http://www.flowingsoftware.com/). Cell surface markers 
CD44/CD24 have been detected using harvested cells incubated for 30 min on ice with anti-
CD44-FITC (Clone G44-26, BD Pharmingen) and anti-CD24-APC (Clone ML5 BioLegend). Cells 
were processed by the BD FACSCalibur. 
For S phase analysis, cells were grown for 3h with ϭϬϬʅM ďƌoŵodeoǆǇuƌidiŶe ;BƌdUͿ. Afteƌ 
fixation, coverslips were treated with 1N HCl (10min, on ice), followed by 20min with 2N HCl 
at room temperature. Mouse anti-BrdU (Sigma) was used as primary antibody. Nuclei were 
stained with Hoechst 33258 (Sigma).  
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Transwell migration assay  
  
For migration assays, cells were plated in the upper well of a transwell chamber separated 
with a filter containing 0.8 µm pore size (Corning) coated with a solution composed 400 µg/ml 
cultrex and DMEM/F12 without EGF in the upper part, while in the lower well complete 
DMEM/F12 was added. After 16h of incubation, cells that migrated through the filter were 
fixed with 4% PFA. Nuclei were stained with Hoechst 33258 (Sigma) and cells were counted 
with Leica AF 6000LX microscope and compared with the random motility of the cells.  
  
Statistics  
  
Results were expressed as means ± standard deviations from at least three independent 
experiments, except for CHIP experiments where standard error was used. Statistical analysis 
was peƌfoƌŵed usiŶg a “tudeŶt’s t test ǁith the leǀel of sigŶifiĐaŶĐe set at P <Ϭ.Ϭϱ. Data fƌoŵ 
3D acinar area measurement was determined using ImageJ image analysis software and 
analyzed using Non-parametric Mann-Whitney test (Prism GraphPad Software). Data were 
from at least three independent experiments. *P<0.05; **P<0.01; ***P<0.005.  
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3. RESULTS 
 
3.1. CRISPR/Cas9 -mediated HDAC7 knockout in MCF10A cells. 
 
With the aim of investigating the involvement of HDAC7 in mammary epithelial homeostasis 
and especially in epithelial morphogenesis and proliferation, we applied the CRISPR/Cas9 
system to obtain human breast epithelial MCF10A-HDAC7-/- cells. Our strategy was to target 
different exons of the HDAC7 gene (Figure 7A). We designed three guides to employ a precise 
targeting of the exons 3, 4 and 5. Guides (gRNAs) were designed with the CRISPR/Design 
software, in order to get guides with the smallest off-targets chance (Figure 7B).  
Each single guide was cloned in the lentiCRISRv2 plasmid and, with the packaged lentivirus, 
three different infections on MCF10A cells were performed.  We also used the empty 
lentiCRISPRv2 to obtain MCF10A-WT cells. After selection, we generated monoclonal cell lines, 
by seeding a single cell in 96 wells plate.  We decided to screen our clones using the 
immunoblotting technique, to unambiguously demonstrate the abrogation of HDAC7 
expression. Hundreds of clones were selected for the analysis and the resulting lysates 
screened by immunoblotting using an anti-HDAC7 antibody that we have generated.  
Curiously, with this preliminary screening we did not found KO clones of MCF10A cells infected 
with the guides against the exon 3. Moreover, few clones of HDAC7-/- cells were isolated with 
the gRNAs targeting exon 4 and 5. On the contrary we obtained a higher number of 
HDAC7+/+and some heterozygous HDAC7 -/+ clones (data not shown). These results suggest a 
possible negative selection versus the HDAC7 KO clones. This selection could be justified by 
the importance of HDAC7 in influencing cell fitness.  
Among the resulting HDAC7-/- clones obtained with the guides against the exon 4 and the exon 
5, we decided to evaluate the corresponding genomic regions by Sanger sequencing. As 
expected, DNA sequencing revealed indels introduction and deletions, possibly through NHEJ, 
in which the alterations of the open reading frame resulted in a premature stop codon, thus 
justifying the absence of the HDAC7 protein (Fig. 7C).  
We selected two MCF10A-HDA7-/- clones. The clone 2.65 was obtained using the gRNA against 
the eǆoŶ ϰ. “eƋueŶĐiŶg pƌoǀed aŶ iŶseƌtioŶ of a siŶgle ŶuĐleotide ͞A͟ ǁithiŶ the eǆoŶ ϰ, thƌee 
nucleotides before the PAM sequence. Because of this insertion, a premature stop codon is 
introduced which causes the lack of the protein expression. Concerning the second 
characterized clone (clone 3b) another insertion is the cause of the HDAC7 loss. In this case, a 
little iŶdel of fouƌ ŶuĐleotides ͞ACCA͟ ǁas pƌeseŶt iŶto the eǆoŶ ϱ of the HDAC7 gene, thus 
producing a premature stop codon (Figure 7C). 
Both clones were selected for further analyses. 
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FIGURE 7: Crispr/Cas9 strategy to knock out HDAC7 in MCF10A cells. 
A: Representation of the human HDAC7 gene. The ATG was placed on the first coding exon. In blue, 
red and green are represented the exons where PAM sequences, are located.  
B: Description of the HDAC7 exons selected to be targeted by Cas9 and by the respective gRNAs 
with the number of putative off-targets genes. 
C: Illustration of the HDAC7 +/+ and HDAC7 KOs sequences. KO clone sequences are described 
showing in red the insertion caused by the NHEJ, which promotes the premature STOP codon 
formation in MCF10A HDAC7-/-cells. In bold are represented the PAM sequences. 
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3.2. Characterisation of the MCF10A HDAC7-/- clones. 
 
To further characterize the generated MCF10A-HDAC7-/- cells, in particular clones 2.65 and 3b, 
we first analysed the protein levels of HDAC4 and HDAC5 (Figure 8A) in order to exclude 
compensatory mechanisms among proteins of the same family. These two proteins are the 
foremost expressed class IIa HDACs in MCF10A, after HDAC7 (Clocchiatti et al., 2015). 
Immunoblot analysis did not evidence compensatory effects. HDAC4 and HDAC5 maintain the 
same expression both in KOs and MCF10A WT cells.  
MEF2 transcription factors are directly regulated by class IIa HDACs (Zhang et al., 2002). 
MEF2A and MEF2D are expressed in MCF10A cells. To verify if the absence of HDAC7 could 
influence their expression, we analysed their levels by immunoblot. No relevant changes can 
be observed in the expression of both MEF2 between KOs and WT cells (Figure 2A).  
Cyclin-dependent kinases (CDKs) are master regulators of cell cycle progression (Besson et al., 
2008). The CDK inhibitor 1A (CDKN1A), also named p21, is a well-known negative regulator of 
proliferation (Lim and Kaldis, 2013). There are evidences that MEF2 and class IIa HDACs could 
be involved in the regulation of CDKN1A transcription (Clocchiatti et al., 2015; Di Giorgio et 
al., 2015). To better understand the effect of HDAC7 on the regulation of p21, we analysed 
CDKN1A protein levels by Western Blotting (Figure 8A). As expected, HDAC7-/- cells showed a 
strong up-regulation of CDKN1A compared with HDAC7+/+ cells. This phenotype could be 
caused by a diminished activity of class IIa HDACs on the CDKN1A promoter where they are 
recruited by MEF2 family members (Clocchiatti et al., 2015). If CDKN1A is up regulated in KOs 
cells, an impact on the cell cycle progression should be evident. To verify this hypothesis, we 
performed some experiments to understand the proliferation rate of HDAC7-/- cells.  
First, a BrdU assay revealed a smaller percentage of HDAC7 -/- cells in S phase compared with 
HDAC7+/+ cells. The percentage of proliferating cells is similar between the two clones and 
fluctuates among 20% to 25%, compared to the ~50% of the WT (Figure 8B). 
Second, we performed a cytofluorimetric analysis to discriminate differences in the cell cycle 
between HDAC7+/+ and HDAC7-/-cells. Not surprisingly, we discovered that the percentage of 
cells in the G1 phase was higher in KOs compared to the control (Figure 8C). In addition, a 
proliferation assay was performed to further confirm the previous data. As predicted, both KO 
cell lines evidenced a significant lower proliferation rates, in comparison with the WT cells 
(Figure 8D). These results support the idea that HDAC7 influences the proliferation of the 
MCF10A cells acting as a repressor of the p21 expression through MEF2.   
When MCF10A cells are plated on a reconstituted basement membrane matrix (rBM), derived 
from a special type of mouse tumour, the Engelbreth Holm-Swann (EHS) murine sarcoma, they 
give rise, through a morphogenetic process, to a 3D acinar structure (Debnath et al., 2002). 
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To demonstrate whether the impact of HDAC7 on cell cycle progression could influence the 
growth of MCF10A cells in 3D condition, we performed a three-dimensional morphogenetic 
assay on MCF10AHDAC7+/+ in comparison with HDAC7-/- (clone 3b) (Figure 8E). Every four days 
images were collected and for each acinus its area was calculated. HDAC7+/+ cells did not 
showed differences in morphology of acini but, from the day 4, a difference in the acinar area 
was evident. The main differences were revealed after 8 and 12 days in 3D culture. These data 
confirmed that the HDAC7 -/- cells are less proliferative compared to the control under 2D as 
well as under 3D culture conditions. 
 
 
 
 
 
Figure 8: MCF10A HDAC7-/- clones characterization. 
A: Immunoblot analysis of HDAC4, HDAC5, MEF2D, MEF2A and CDKN1A expression in MCF10A 
HDAC7-/- clones (2.65 and 3b) RACK1 was used as loading control. 
B: BrdU positive assay was performed with MCF-10A KO clones. After 24h from seeding BrdU 
was added for 3h. After fixation cells were processed for immunofluorescence to score the 
percentage of BrdU positive cells 
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C: FACS analysis of MCF10A HDAC7-/- clones. Cells were fixed with ethanol, treated with Rnase A and 
stained with propidium iodide. 
D: The graph represents the proliferation curves obtained counting the number of cells after 1, 2, 3, 
5 and 7 days in culture as indicated. Only alive cells were considered after Trypan blue counting. 
E: AĐiŶaƌ size ;ʅŵϮͿ of MCF-10A WT and the clone 3b, in 3D culture for 4, 8, 12 and 16 days. Culture 
medium was changed every 4 days. Data are presented as percentage relative to day 1 WT cells. 
 
 
 
3.3. HDAC7 WT re-expression in KO rescues the phenotype. 
 
Today the relevance of the CRISPR/Cas9 technique for genome editing is well affirmed. It is an 
efficient system, frequently applied in vitro experiments, which seems to have promising 
potentialities for in vivo applications, with therapeutic perspectives. Even if the power of this 
system is confirmed day by day, the off-target effects represent a dark side of this 
revolutionary technique. The possibility that Cas9 can edit the target gene and other genes is 
a problem that researchers must climb over. In our specific case, we wanted to prove that the 
phenotype described previously was directly related to the HDAC7 knock-out. To affirm this, 
we infected KO cells with the inducible form HDAC7 WT-ER, in order to re-express HDAC7 in 
MCF10AHDAC7-/- cells. To verify and confirm the stable expression of the HDAC7 protein in 
KO cells, we performed an immunoblotting and an immunofluorescence analysis, after 
induction with 4-OHT (Figure 9B and C). After proving the re-expression of HDAC7 in KO cells, 
we investigated p21 protein levels. In immunoblot analysis, p21 appears strongly down-
regulated after HDAC7 re-expression in KO cells (Figure 9C). This down-regulation was 
confirmed at mRNA level by qRT-PCR analysis (Figure 9E). A BrdU assay was performed to 
testify the rescue of the proliferative defect in MCF10A KO/HDAC7 WT-ER cells in comparison 
with the KO/ER cells (Figure 9D).  
We further investigated the recovery of the proliferative defect also in 3D culture. After four 
days from the seeding of WT, KO and KO/HDAC7-ER cells on Cultrex, in cells re-expressing 
HDAC7 compared to the KO, the acinar size was increased and indistinguishable from WT 
MCF10A cells (Figure 9A). 
All these results confirm a rescue of the phenotype in MCF10A HDAC7 KO cells after the re-
expression of HDAC7.  In summary, we can exclude that the deficit of proliferation observed 
in HDAC7 KO cells originate from the off-target activity of Cas9. 
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Figure 9: HDAC7 expression in MCF10A HDAC7-/-. 
A: AĐiŶaƌ size ;ʅŵϮͿ of MCF-10A HDAC7+/+, HDAC7-/-. and HDAC7-/-/HDAC7-ER in 3D culture for 4 
days. 4-OHT was added in culture medium every two days to induce HDAC7 expression. 
B: Confocal pictures of MCF10A cells expressing HDAC7-ER (green). AF546-phalloidin was used to 
stain F-actin and nuclei were stained with Topro-3. Scale bar, 50 µm. 
C: Immunoblot analysis of HDAC7 and p21 in MCF10A HDAC7+/+, HDAC7-/-. and HDAC7-/-/HDAC7-
ER cells. Actin was used as loading control. 
D: BrdU positive cells percentage of MCF-10A HDAC7+/+, HDAC7-/-. and HDAC7-/-/HDAC7-ER cells. 
Cells were seeded and after 24h BrdU was added for 3h. After fixation cells were processed for 
immunofluorescence.   
E: mRNA expression levels of the MEF2-target gene CDKN1A were measured by using qRT-PCR in 
MCF-10AHDAC7+/+, HDAC7-/-. and HDAC7-/-/HDAC7-ER cell. 4-OHT was added to culture medium 
the day of seeding.  
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3.4. HDAC7 contribution in stemness in MCF10A cells. 
 
Recent observations have ruled out a possible contribution of HDACs and in particular of 
HDAC7 in the maintenance of stemness in the breast epithelium, with important impacts on 
cancer growth (Clément et al., 2017). Hence, we asked if HDAC7 could contribute to stemness 
also in our experimental model of epithelial mammary cells.  
Within a cell population are present some cells that show stem characteristics and play a 
pivotal role in the stem community maintenance (Joshi et al., 2012). Even if MCF10A cells are 
considered differentiated cells, among them, are present some progenitors, at very low 
percentage with stem features (Qu et al., 2015).    
We decided to prove the involvement of HDAC7 in the regulation of stem cells by performing 
a mammospheres assay. This assay is based on the stem cell ability to grow in ultra-low 
adhesion plates, helping the discrimination with the differentiated cells, which are not able to 
grow under these conditions. After 10 days in culture, progenitors of the differentiated cells 
survive and proliferate to generate spheres (in case of mammary stem cells, they are also 
named mammospheres). Comparing the HDAC7+/+ with MCF10A-HDAC7-/- we observed a 
reduced number of spheres formation in the case of HDAC7-/- cells (Figure 10A and B). The 
demonstration that HDAC7 is a critical determinant in the regulation of stemness, comes from 
the experiments with MCF10A KO/HDAC7-ER. When HDAC7 was re-expressed in knocked-out 
cells, they reacquire the capability of generating spheres (Figure 10D and E).  
The reduced number of mammospheres, observed in the absence of HDAC7, suggests for a 
reduction or for a defect in cells with stem characteristics. Moreover, a smaller area was 
detected in the few mammosphers derived from KO cells compared to MCF10A WT cells 
(Figure 10C and E).  
Moreover, we used flow cytometric analysis to determine the CD44high/CD24low phenotype in 
MCF10A WT and HDAC7-/- cells. CD44high/CD24low cells could be considered undifferentiated 
cells, on the contrary, CD44high/CD24high cells exhibit differentiated properties. We observed 
that MCF10A HDAC7-/- exhibited a small but significant decrease in the CD44high/CD24low 
population (5,78+3.84 versus 8,33+3,15 p=0,0498) compared with the MCF10A WT, as 
evidenced in Figure 10F and G. This experiment confirms the role of HDAC7 in sustaining 
proliferation and argue for an additional contribution in stemness. 
BMP4 (bone morphogenetic protein 4) is a protein belonging to the TGF-β super family. Its 
involvement in the regulation of mammary epithelial stem cells is well known (Clément et al., 
2017). To increase the pool of cells with stem characteristics, we pre-treated KO and WT cells 
with BMP4 in 2D culture. After two days, pre-treated cells were used for sphere assay. After 
10 days, the number of mammospheres formed by the WT cells was significantly higher 
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compared to untreated cells (Figure 10H). Curiously MCF10A/HDAC7 KO cells BMP4-treated, 
increased the number of spheres, compared with the untreated ones, but they are 
significantly less compared to WT cells pre-treated with BMP4. These data show that BMP4 
treatment can augment the pool of cells with stem features. However, HDAC7 KO cells 
maintain the original defect in terms of sphere formation efficiency. In addition, the dimension 
of sphere generated by KO cells treated with BMP4, again appeared smaller compared to WT 
cells BMP4-treated.  
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Figure 10: HDAC7 contributes in stemness maintenance in MCF10A cells. 
A: Mammosphere assay was performed seeding 1000 cells of each cell line. Spheres with area > 
50µm were counted using Leica AF 6000LX microscope after 10 days of culture. Each dot represents 
an experiment. 
B: Images represent mammospheres obtained after 10 days of culture respectively from WT and KO 
cells. Images were collected using Leica AF 6000LX microscope. Scale bar, 100 µM. 
C: “pheƌe aƌea ;ʅŵϮͿ fƌoŵ MCFϭϬA WT aŶd KO plotted as a ďoǆ plot. 
D: Images representing mammosphere resulted from MCF10A WT, KO and KO/HDAC7-ER cells. 
Images from Leica AF 6000LX microscope. Scale bar, 100 µM 
E: Box plot representing the size of spheres generated by WT, HDAC7-/- and MCF10A KO/HDAC7-ER 
cells as indicated. 
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F: Representative flow cytometry data from double staining MCF10A WT and HDAC7-/-. Cells were 
incubated with FITC-conjugated CD44 and APC-conjugated CD24 for 30 min in ice at concentrations 
recommended by the manufacturer.  Isotype control double staining for CD44 and CD24 from both 
cell lines is shown. 
G: FACS analysis of the double staining for CD44 and CD24 surface markers. Seven experiments have 
been collected. 
H: The panel shows the results from 3D sphere assays obtained with cells treated with BMP4. 
MCF10A HDAC7 KO and WT cells were pre-treated 2 days with 15ng/ml of BMP4 and then seeded 
in Ultra Low Adhesion plates. After 10 days, spheres with an area larger 50µm were counted. Each 
dot represents an experiment. 
 
 
 
3.5. Gene expression profiles under HDAC7 influence.  
 
Microarray analysis of MCF10A and MCF10A-HDAC7-/- cells was performed to unveil changes 
in gene expression under HDAC7 supervision. To prove that fluctuations in gene expression 
were a specific consequence of HDAC7 absence, the comparative analysis included the gene 
expression profile of MCF10A cells re-expressing the inducible version of HDAC7 (KO/HDAC7-
ER). The DNA microarray analysis identified 205 genes significantly down-modulated and 272 
genes significantly up regulated in HDAC7-/- cells (Figure 11A). If we consider the fold changes 
of 477 DEGs (differentially expressed genes), IL24, CCL20 and FBOX32 resulted strongly up-
regulated in HDAC7-/- cells. On the other hand, SPRR3, SPRR1A and KRTDAP showed the 
strongest down-regulation (Figure 11B).  In a preliminary analysis, we focused our attention 
on genes up-regulated in HDAC7-/- cells. The Gene Set Enrichment Analysis (GSEA) algorithm 
was used in conjunction with the Molecular Signatures Database (MSigDb) to confer different 
biological functions to genes modulated by HDAC7 (Figure 11C). Categories underlined in the 
hallmark gene set analysis showed the regulation of genes involved in the inflammatory 
response (interferon α and γ responses), xenobiotic response and extracellular matrix 
remodelling. Analysing DEGs for the GO biological process identified as the top ranching 
processes: defence response, response to external stimulus and negative regulation of cell 
proliferation. Moreover, the top Go-term analysis revealed the up-regulation of the GO-term 
signal peptide in HDAC7-/- cells. These evidences indicate that HDAC7 profoundly reprogram 
the expression profile of the secretome, including the inflammatory stress response, cell 
proliferation, cell adhesion. Overall these studies indicate that HDAC7 could supervise 
expression of genes involved in the remodelling of the microenvironment. 
Another microarray study was performed to better understand the involvement of HDAC7 in 
the regulation of stemness. The transcriptomes of HDAC7+/+ and HDAC7-/- cells treated with 
BMP4 was compared. This study evidenced the up-regulation of 264 genes in HDAC7-/-, 182 in 
HDAC7+/+ cells treated with BMP4 compared to untreated. 75 of these genes were common, 
ďetǁeeŶ the tǁo Đell liŶes ;Figuƌe ϭϭDͿ. As eǆpeĐted, G“EA of the Đategoƌies ͞Hallŵaƌk geŶe 
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set͟, ͞KEGG geŶe set͟ aŶd ͞OŶĐogeŶiĐ sigŶatuƌe geŶe set͟, ƌeǀelled a stƌoŶg aĐtiǀatioŶ of the 
TGF-β signalling pathway in both cell lines. In addition, HDAC7-/- cells treated with BMP4 
showed an up-regulation of genes down-regulated by the KRAS activation (Figure 11E).   
Concerning down-regulated genes in HDAC7+/+ and HDAC7-/- treated with BMP4, a list of 173 
genes resulted down-modulated in HDAC7+/+ and 63 in HDAC7-/-. Among them 30 are genes 
commonly regulated in both cell lines (Figure 11F). As illustrated in figure 11F, most of the 
transcriptional response promoted by BMP4 is common between HDAC7+/+ and HDAC7-/- cells 
(activation of TGFβ signalling, blunting of KRAS signalling and activation of EMT mechanisms). 
However, a differential response to extracellular stimulation/remodelling after BMP4 
treatment could be observed between HDAC7-/- and HDAC7+/+ cells by focusing the attention 
on the 143 genes down-regulated by BMP4 only in HDAC7+/+. GSEA analysis groups these 
genes in categories enriched for the response to oestrogen and in co-culturing MCF10A cells 
with cancer-associated fibroblasts and among the genes up-regulated in basal subtype of 
breast cancer samples (Figure 11G). 
Radar charts in figure 11H, summarize the microarrays results, underlining the HDAC7-
regulated genes in selected pathways and gene families. In fact, among the up-regulated 
genes we found interleukins (IL1B, IL1A, IL8, IL32), which confirms the activation of the 
inflammatory response. In particular IL8 is known to be a MEF2 target in LMS cell lines (Di 
Giorgio et al., 2017). The activation of the inflammatory response in MCF10A HDAC7-/- cells 
was also confirmed by the up regulation of C-C motif chemokine ligands (CCL5, CCL8, CCL20). 
Furthermore, a fraction of the up-regulated genes encodes for proteins involved in the 
inflammatory response mediated by interferon γ aŶd α as pƌoǀed ďǇ the up ƌegulatioŶ of IFNA 
and of the ubiquitin-like protein interferon-stimulated gene 15 (ISG15). Finally, HDAC7 seems 
to have minor impacts on genes of the (TNF) tumor necrosis factor family, whereas important 
influences are played on genes of the IGF-1 pathway (IGFBP3, IGFBP6, IGFBP7, IGFL1, IGFL2, 
IRS1, IRS2), which includes well-known negative regulators of stemness (Farabaugh et al., 
2015).  
To validate the microarray data, we further confirm the gene expression profile of the up-
regulated genes, described before, by RT-PCR (Figure 11I). We analysed the mRNA expression 
levels of IGFBP6, IGFBP7, IL24, IL8, ERRFI1, FBOX32 and ISG15 and all resulted up-regulated in 
KO cells. All these experiments included also MCF10A-KO/HDAC7 and WT-ER cells, thus 
confirming that the fluctuations were specifically caused by HDAC7 absence. Moreover, to 
exclude genes regulated by tamoxifen, both the microarray analysis and the RT-PCR 
experiments were performed by comparing also KO cells and the KO-ER cells (treated with 4-
OHT). Considering this parameter, we can affirm that genes investigated are directly or 
indirectly regulated by HDAC7 without tamoxifen influence.  
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MEF2 family members are the favourite class IIa HDACs binding partners (Di Giorgio and 
Brancolini, 2016). These proteins act as transcriptional factors and regulate the expression of 
different genes in different tissues. To estimate if the up-regulation of some genes in HDAC7-
/- is  influenced by the MEF2-HDACs axis, we analysed the expression of the selected genes in 
MCF10A cells expressing a conditionally active form of MEF2D fused to the VP16 activation 
domain of herpes simplex virus (Flavell, 2006) A MEF2D DNA-ďiŶdiŶg defeĐtiǀe ŵutaŶt ;ΔDBDͿ 
form was used as control. IL8, IL24, ERRFI1 and FBOX32 resulted up-regulated in MCF10A cells 
expressing MEF2D-VP16, on the contrary, IGFBP6 and 7 resulted not significantly regulated by 
MEF2D (Figure 11J). These data prove the important role of MEF2 as target of HDAC7 but also 
unveil MEF2-independent activities for this class IIa HDAC, particularly on the repression of 
IGFBP6 and 7 genes. 
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Figure 11: Expression profiles of MCF10A HDAC7-/-. 
A: Pie-chart indicating the number of genes significantly up and down-regulated in HDAC7-/- 
compared to HDAC7+/+ and HDAC7-/-HDAC7-ER MCF10A cells.  
B: Histogram representing the HDAC7 signature in MCF10A cells, by comparing HDAC7-/- cells 
with HDAC7+/+ HDAC7-/-HDAC7-ER cells. The top regulated genes are highlighted.  
C: Enrichment analysis was performed to investigate the biological processes promoted by 
HDACϳ depletioŶ iŶ MCFϭϬA Đells. M“igDB ͞Hallŵaƌks͟ aŶd GeŶe oŶtology (GO) categories were 
investigated. The significance of the obtained enrichment for each category is scored as Fold 
enrichment, p-value and FDR. The percentage of gene calling/overlap for each gene set is shown.    
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Figure 11: Expression profile of MCF10A HDAC7-/-. 
D: The Venn diagram shows genes-up regulated in MCF10A WT and KO cells after BMP4 
treatment. 
E: Enrichment analysis on genes up-ƌegulated afteƌ ϭϱŶg/ŵl BMPϰ tƌeatŵeŶt. ͞Hallŵaƌk͟, 
͞KEGG͟ aŶd ͞OŶĐogeŶiĐ sigŶatuƌe͟ Đategoƌies ǁeƌe iŶǀestigated. The significance of the 
obtained enrichment for each category is scored as genes in overlap, p-value and FDR.  
F: The Venn diagram shows genes down-regulated in MCF10A WT and KO after BMP4 treatment. 
G: GSEA on gene down-regulated in HDAC7+/+ and HDAC7-/- cells treated with BMP4. 
͞Hallŵaƌk͟, ͞CheŵiĐal aŶd geŶetiĐ peƌtuƌďatioŶ͟ aŶd ͞OŶĐogeŶiĐ sigŶatuƌe͟ geŶe sets ǁeƌe 
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used. The significance of the obtained enrichment for each category is scored as genes in overlap 
p-ǀalue aŶd FDR. ͞Hallŵaƌk͟ aŶd ͞CheŵiĐal aŶd geŶetiĐ peƌtuƌďatioŶ͟ geŶe sets ǁeƌe used to 
describe the pool of gene down-regulated in MCF10A WT+BMP4. 
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Figure 11H: Radar charts represent gene families and pathways in which HDAC7 is involved. 
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Figure 11: Expression profile of MCF10A HDAC7-/-. 
I: mRNA expression levels of IGFBP6, IGFBP7, FBOX32, ERRFI1, IL8, IL24 and ISG15 were 
measured by using qRT-PCR in MCF-10A WT, KO, KO-ER and KO/HDAC7-ER. 4-OHT was added to 
culture medium the day of seeding. 
J: The MEF2 influence on the expression levels of genes up-regulated in MCF10A-KO cells was 
tested using qRT-PCR. The mRNA expression levels of IGFBP6, IGFBP7, FBOX32, ERRFI1, IL8, IL24 
and IL32 in MCF10A expressing MEF2/VP16-ER and MCF10A MEF2/∆DBD-ER was used as 
control. 
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3.6.  HDAC7 participates in the maintenance of the stem cell niche environment. 
 
The microarray analysis unveiled, an up-regulation of the IGFBPs in MCF10A-HDAC7-/- cells. 
Hence, we asked if HDAC7 could have a role in the stem cell niches through the release of 
niche factors, capable of promoting stemness. IGFBPs interact with IGF-1, causing a reduction 
of its bio-availability. IGF-1 is considered a factor important for the stem cells renewal and it 
is released by the stromal cells (Zhao et al., 2017). Considering these evidences, we supposed 
that HDAC7 represses the transcription of the IGFBPs (in particular IGFBP 3, 6 and 7) to sustain 
the activation of the IGF-1 pathway in stem cells. We decided to pre-treat WT and KO cells 
with 15ng/ml of IGF-1 for two days and then we seeded treated cells in ultra-low adhesion 
plates to allow mammopsheres formation (Figure 12A). After 10 days in culture, we analysed 
the sphere number. As expected, IGF-1 promoted the formation of mammosphere also in KO 
cells. However, HDAC7-/- cells pre-treated with IGF-1 still formed less spheres compared to 
HDAC7-+/+ cells. No evident differences were detected between cells pre-treated and cells 
treated throughout the ULA culture, with 15ng/ml of IGF-1.  
It is possible that IGF-1 is less bio-available in KO cells environment and this influences the 
stem cells growth and renewal.  
Since an important fraction of genes under HDAC7 regulation encode for secreted proteins, 
we supposed that HDAC7 expression can influence the microenvironment by controlling the 
release of niche factors important for the mammary epithelial stem cells 
growth/maintenance. In order to investigate this hypothesis, we cultivated HDAC7+/+ and 
HDAC7-/- in ULA condition with different conditioned medium. To perform this experiment, 
WT and KO cells were seeded in adhesion plates for two days using the mammospheres 
medium. Conditioned medium was obtained from HDAC7+/+ and HDAC7-/- cells and used to 
cultivate HDAC7+/+ and HDAC7-/- mammospheres.  
Overall, growing MCF10A in conditioned medium generated higher numbers of 
mammospheres. Specifically, WT cells plated with the medium conditioned by themself 
showed a higher number of spheres compared to the WT grown with the conditioned medium 
from MCF10A KO cells (Figure 12B). The same conditions were repeated with HDAC7-/-cells. 
KO mammospheres grown with the medium conditioned either by the WT and by KO cells 
generated more spheres respect to HDAC7-/- cells without conditioned medium. In this case 
the intrinsic nature of the KO is not sufficient to take full advantage from factors released by 
WT cells in the microenvironment. This experiment proves again the reduced presence of 
stem progenitors in MCF10A HDAC7 KO cells and the involvement of HDAC7 in the niche 
factors release. As a matter of fact, the medium conditioned with the WT cells is richer of 
factors that influence the stem growth compared to the medium conditioned by the KO cells.  
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Figure 12: HDAC7 regulates the stem factors releasing inducing stemness maintanence.  
A: 3D sphere formation assays was used to demonstrate the IGF-1 effect on MCF10A HDAC7 KO and 
WT during spheres formation. The plot represents respectively data obtained from WT and KO cells 
without IGF-1 treatment (-), pre-treatment with 15ng/ml IGF-1 (+) and pre and post seeding 
treatment (+P). Mammosphere assay was performed seeding 1000 cells for each cell line. After 10 
days spheres with > 50µm area were counted using Leica AF 6000LX microscope. 
B: 3D sphere formation assay was used to demonstrate the conditioned medium effect on MCF10A 
WT and KO during spheres formation. The plot represents respectively data obtained from WT and 
KO cells without conditioned medium (-), conditioned medium with WT (+/+) conditioned medium 
with KO medium (-/-). Mammosphere assay was performed by seeding 1000 cells for each cell line. 
After 10 days spheres with > 50µm area were counted using Leica AF 6000LX microscope. 
 
 
 
3.7. HDAC7 loss in MCF10A-HRAS negatively impacts on cell proliferation, migration 
and acini morphology/invasiveness under 3D culture. 
 
Supposing a contribution of HDAC7 in breast cancer progression, normal immortalized breast 
MCF10A and MCF10A-HDAC7-/- cells were infected with a retroviral vector that promotes a 
stable expression of HRAS G12V oncogene. First of all, we inspected the RAS expression in WT-
HRAS and KO-HRAS cells to verify an equal amount of this protein in both cell lines. 
Furthermore, we checked the p-ERK levels as marker of RAS activation (Figure 13A). Finally, 
we evaluated HDAC7 expression. Interestingly we discovered an up-regulation of HDAC7 in 
RAS-transformed cells (Figure 13A). This data reinforces a hypothetical role of HDAC7 in 
neoplastic transformation.  
In order to test this hypothesis, a BrdU proliferation assay was performed on MCF10A WT, 
MCF10A-HRASV, MCF10A HDAC7-/- and MCF10A-HRAS-HDAC7-/- (Figure 13B). As expected, 
RAS expression impacts on cell proliferation. Remarkably, the removal of HDAC7 in a RAS 
context still strongly impacted on DNA replication. This result makes evident a contribution of 
HDAC7 to the proliferation also in RAS-transformed cells. 
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A transwell migration assay was next executed to determine if HDAC7 loss can also influence 
the migration proprieties of transformed cells. Considering the ratio between the invading 
cells and their random migration is evident that MCF10A-HRAS-HDAC7-/- cells show less 
motility compared with the transformed HDAC7 WT cells. This finding reveals that HDAC7 can 
control the invasiveness of RAS-transformed cells unveiling a role of HDAC7 in cancer cell 
migration (Figure 13E). 
3D culture of RAS-transformed MCF10A cells give rise to acini with an altered morphology, 
characterized by a stellate shape instead of a spheroid shape (Imbalzano et al., 2009). To 
investigate a contribution of HDAC7 in this altered morphogenic process, we performed a 3D 
culture with MCF10A-HRAS and MCF10A-HRAS-HDAC7-/- cells. Acini shape was scored after 8 
days and 12 days of culture (Figure 13F). After 8 days on Cultrex, MCF10A-HRAS showed a 
higher percentage of stellate shaped acini compared to spheroid ones.  Opposite results were 
obtained counting the stellate shaped acini of MCF10A-HRAS-HDAC7-/- cells. At day 12 these 
results were confirmed, demonstrating an impact of HDAC7 on RAS-transforming capability 
(Figure 13C and D). Since previous experiments described a role of HDAC7 in stemness, we 
investigated the involvement of HDAC7 on cancer stem cells growth. To this end, we cultivated 
in ULA condition MCF10A-WT; MCF10A-HRAS and MCF10A-HRAS-HDAC7-/- cells (Figure 13G). 
After 10 days in culture mammospheres were counted and analysed. RAS oncogene did not 
increase the number of generated mammosphere. Interestingly MCF10A-HRAS-HDAC7-/- cells 
generated a very small number of spheres compared with MCF10A-HRAS cells. This result 
demonstrates that HDAC7 can control the stem cells potential also in RAS-transformed cells.  
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Figure 13: HDAC7 loss reduces the transformed phenotype of MCF10A HRAS cells. 
A: Immuonoblot analysis of HRASV12, pERK 1/2 and HDAC7 in MCF10A-WT; MCF10A-RASV12 and 
MCF10A-RASV12-HDAC7-/-. Actin was used as loading control.  
B: BrdU positive cells percentage of MCF-10A-WT, MCF10A-HDAC7-/-. MCF10A-RASV12 and 
MCF10A- RASV12-HDAC7-/-. Cells were seeded and after 24h BrdU was added for 3h then, cells were 
processed for immunofluorescence.   
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C: Images representing the difference between spheroid and stellate shaped acini in a 3D culture 
after 12 days of culture. 
D: Confocal images showing the comparison of stellate acini with spheroid acini. AF546-phalloidin 
was used to stain F-actin and nuclei were stained with anti HMGA2 (green). In lower part, the Z-
section is shown as indicated.  
E: Transwell migration assay of MCF10A-WT; MCF10A-HRAS and MCF10A-HRAS-HDAC7-/-. The 
percentage of migrating cells was calculated through the ratio between the number of invasive cells 
and the random migrating cells. 
F: Percentage of spheroid and stellate acini in MCF10A-WT; MCF10A-RASV12 and MCF10A-RASV12-
HDAC7-/-, after 8 and 12 days in culture. 
G: 3D sphere formation assay was used to demonstrate the role of HDAC7 role in cancer stem cells. 
Spheres were obtained from MCF10A-WT; MCF10A-RASV12 and MCF10A-RASV12-HDAC7-/-.  
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4. DISCUSSION 
 
During a ǁoŵaŶ’s life, ŵaŵŵaƌǇ glaŶds aƌe susĐeptiďle to different processes, which include 
pubertal development, pregnancy, lactation and involution.  The mammary gland is 
represented principally by two different cell types: luminal epithelial cells and basal epithelial 
cells.  The luminal cells are cells involved in ductal and acinar lumen formation of the 
mammary tree. They represent a heterogeneous population of cells where differentiated and 
progenitor cells can coexist. They are responsible for milk production, during lactation and 
they can be interested by the neoplastic transformation. The luminal cells are surrounded by 
a layer of myoepithelial cells. These cells have contractile properties and are responsible of 
the basal membrane production. 
To investigate the morphogenetic process and the transformation of human mammary gland 
in vitro, a widely used cellular model is represented by the immortalised mammary human 
epithelial cells MCF10A grown under 3D conditions. (Schmeichel and Bissell, 2003).  
Class IIa HDACs are important regulators of cell-fate decision by modulating epigenetic 
changes linked to gene transcription and silencing (Di Giorgio and Brancolini, 2016). Among 
the class IIa HDACs, HDAC7 is the most expressed in breast tissue and in particular in MCF10A 
cells. When ectopically expressed, HDAC7 can influence the proliferation of MCF10A cells 
(Clocchiatti et al., 2015). Knockout of the Hdac7 gene in mice results in embryonic lethality 
due to the disaggregation of the cell-cell junctions and consequent rupture of blood vessels 
integrity (Chang et al., 2006). To date, the study of the HDAC7 functions in breast human cells 
was supported only by the shRNA technology (Witt et al., 2017) or by specific HDACs inhibitors 
(Duong et al., 2008).  
 
The role of HDAC7 in the control of mammary cells proliferation 
In this thesis, we took advantage from the CRISPR/Cas9 technology to knockout HDAC7 in 
MCF10A cells. The project was aimed to characterise the phenotype resulting from HDAC7 
abrogation. The difficulty to obtain HDAC7-/- cells, compared with the higher amount of the 
WT and HDAC7+/- cells achieved, suggests a negative selection induced by the absence of 
HDAC7. In literature, some evidences describe that HDAC7, in DP thymocytes, is required to 
maintain normal thymocyte viability (Kasler et al., 2011; Kasler et al., 2017;Hart et al., 2015). 
In literature, is well know that class IIa HDACs act on the CDKN1A expression (Liu et al., 2009; 
Mottet et al., 2009). In 2014 was published that MEF2–HDAC axis controls the cell cycle 
progression by modulating CDKN1A expression in MCF10A (Clocchiatti et al., 2015). In 
particular, the recruitment of HDAC7 on the CDKN1A promoter takes place at the +1.5 Kb 
region, which is under the MEF2s control (Ernst et al., 2011). This data can explain the up-
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regulation of the CDKN1A expression in HDAC7-/- cells. The up regulation of p21 in HDAC7-/- 
clones, unequivocally supports the idea that HDAC7 influences the cell cycle progression of 
MCF10A cells, by acting as a repressor of the p21 expression. Further ChIP experiments need 
to be done in order to understand the regions bound by HDAC7 on the CDKN1A promoter. 
Risks of off-target effects are the dark side of the CRISPR/Cas9 technique. The possibility of 
getting unwanted phenotypes by the deletion of different targets from the investigated one, 
must be taken into account (Zhang et al., 2015;Schaefer et al., 2017). Rescue experiments are 
considered the most straightforward approach to fight the off-targets effects (Graham and 
Root, 2015). A strategy is to re-express, in KO cells the target gene, which lack of the PAM 
sequence,  in order to prevent the Cas9 editing (Kwart et al., 2017). Importantly, several 
evidences in literature describe that, through the time, the Cas9 activity is reduced (Anders 
and Jinek, 2016; Zhou et al., 2014; Anders and Jinek, 2016) and a rescue of the phenotype with 
a WT form of the gene is possible (Peng et al., 2016).  In this work, the rescue of the phenotype 
with a WT form of HDAC7 indirectly proved the absence of Cas9 activity in the selected clones. 
Reintroduction of HDAC7 unambiguously demonstrated the role of HDAC7 in the control of 
proliferation and CDKN1A expression in MCF10A cells. 
 
The role of HDAC7 in the control of the stem cell properties of MCF10A 
Stem cells are necessary to sustain  lobules and ducts growth  during puberty and pregnancy 
(Petersen and Polyak, 2010; Zhao et al., 2017). Adult stem cells are distributed long the 
mammary gland among differentiated epithelial cells (Joshi et al., 2012). To date, evidences 
that illustrate a role of class IIa HDACs in stemness maintenance are limited. Zhuang et al., in 
2013, explained for the first time, how class IIa HDACs can regulates cell reprogramming. It 
was described that in fibroblasts expressing the Yamanaka factors, class IIa HDACs, through 
the repression of MEF2, support the reprogramming of these cells from differentiated cells to 
iPSCs (Zhuang et al., 2013).  
More recent data, proposed a relevant contribution of HDAC7 to breast stem maintenance. 
Knock-down of HDAC7, negatively impacts on stem cells growth (Witt et al., 2017). We proved 
that HDAC7 impacts on sphere formation of MCF10A-HDAC7-/- cells, an assay used to evaluate 
the number of stem cells (Eirew et al., 2008). HDAC7-/- cells generated less mammospheres 
and they were smaller compared to WT. Hence, HDAC7 not only controls cell proliferation 
(dimension of sphere) but also the number of cells capable of generating these structures.  
CD44 and CD24 have been used extensively in combination or with other putative markers to 
identify stem cells in a cell population.  We applied the cytometric analysis to compare the 
percentage of the CD44high/CD24low between MCF10A HDAC7-/-  and HDAC7+/+ cells. The small 
but significant reduced number of CD44high/CD24low cells in the HDAC7-/- population, 
compared to HDAC7+/+  further suggests a role of HDAC7 in progenitors preservation. It was 
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proved that BMP4 treatment is sufficient to increase stemness in MCF10A cells (Clément et 
al., 2017). We confirmed this observation. However, although mammospheres were formed 
also in HDAC7-/- in response to BMP4 treatment, they were always less numerous compared 
to WT cells.  
The microarray studies discovered an up-regulation of genes involved in the inflammatory 
response in HDAC7-/- cells. IL24, IL8 and CCL20 were among the highest up-regulated genes in 
MCF10A HDAC7-/- cells. Furthermore, also the interferon-γ was induced in HDAC7-/- cells, as 
proved by the up-regulation of ISG15. Future experiments will be conducted to better 
understand the role of HDAC7 in the repression of the inflammatory response. 
Importantly, much of the pro-inflammatory response triggered in HDAC7 KO cells is blunted 
after BMP4 treatment, with exception of CCL20. Thus, the partial effect on spheres formation 
in HDAC7 KO cells could depend on the suppression of the inflammatory response (Chang et 
al., 2016; Yeh et al., 2016).  
It was reported that class IIa HDACs promotes muscular atrophy by repressing Dach2, by 
activating the transcription of Myogenin and its targets, the E3-ligase Atrogin-1/FBOX32 and 
MURF1 (Tintignac et al., 2015). Our microarray analysis showed an up-regulation of the 
FBOX32 gene in HDAC7 KO cells. 
Another gene significantly up-regulated in MCF10A HDAC7-/- cells was ERRFI1, a negative 
regulator of several EGFR family members. Interestingly, ERRFI1 expression was previously 
demonstrated being sensitive to SAHA treatment and HDAC4 expression (Clocchiatti et al., 
2013; Dudakovic et al., 2013).  
Members of the IGFBPs family (IGFBP3,6,7) were also significantly induced in HDAC7-/- cells. 
The IGFBPs are involved in the recruitment of free IGF-1 (Hwa et al., 1999). In literature the 
role of IGF-1 in stemness is well known (Le Coz et al., 2016; Farabaugh et al., 2015). As a matter 
of fact, it was discovered that IGFBP6, alters skeletal muscle differentiation of human 
mesenchymal stem cells (Aboalola and Han, 2017). Specifically, experimental evidences 
describe that IGFBP6 exposure activates the muscle lineage commitment by increasing the 
expression of muscle-specific markers such as MyoD, MyoG, and MHC.  
In literature, the contribution of IGFBP7 in stem niche was recently reported. In Drosophila 
melanogaster, the homolog of IGFBP7 is called ImpL2. The down-regulation of ImpL2 prevents 
InR activation in somatic stem cells and most importantly it prevents differentiation by 
inhibiting PI3K/Tor pathway activity (Amoyel et al., 2016). Finally, the important contribution 
of IGF-1 network in stemness regulation found validation in IGF-1 itself. IGF-1 can be 
considered as a niche factor released by the stem niche cells to increase the stem cells renewal 
(Zhao et al., 2017).  
The regulation of IGFBPs in HDAC7 KO cells unveils a new role of HDAC7 in the regulation of 
the stem niche factors release. In fact, we demonstrated that HDAC7 can down-regulate the 
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expression of IGFBPs, which are mandatory to sustain the IGF-1 signalling and thus recovering 
spheres formation potential.  
As predicted, spheres that have been obtained from HDAC7-/- treated with IGF-1 were less 
than the control.  A phenomenon that could be explained by the up-regulation of IGFBPs in 
HDAC7-/- cells.  
All these data suggest two possible functions of HDAC7 in stem cell growth and self-renewal. 
On one side, we could hypothesize a role of HDAC7 in sustaining different pathways included 
the IGF-1 signalling pathway, contributing to stem cells fitness and spheres formation (Figure 
14). This hypothesis points to an intrinsic role of HDAC7 as epigenetic regulators in the 
epithelial stem cells being part of the IGF-1 signalling pathway (but not only). This intrinsic role 
could also explain the partial rescue of the sphere formation in BMP4, IGF-1 and WT 
conditioned medium from HDAC7-/- cells. On the other side, HDAC7 can be undoubtedly be 
important for the IGF-1 availability within the microenvironment, through the suppression of 
IGFBPs and of an inflammatory response. The experiments performed with the conditioned 
medium confirmed this function of HDAC7. In fact, the medium conditioned from HDAC7+/+ 
cells is richer of factors that influence the stem growth compared to medium conditioned from 
HDAC7-/- cells. 
If we consider HDAC7 in the mammary gland context, we can suppose that this protein acts 
within stem cells by sustaining the growth of this tissue. In addition, through the influence on 
the microenvironment, HDAC7 can contribute to the release of niche factors (Figure 14). 
Further analysis will be necessary to investigate about the recruitment of HDAC7 on the 
promoters of the IGFBPs. We confirmed with the expression of a conditionally active form of 
MEF2D that the IGFBP6 and 7 expression is not directly regulated by MEF2D. Additional 
transcription factors such FOXA1 and RXR could be involved in the IGFBPs transcription and 
being under the supervision of HDAC7 to orchestrate the necessary epigenetic changes 
(Imamura et al., 2012).  
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Figure 14: Rapresentation of the HDAC7 possible effect on the niche microenvironment. 
 
 
HDAC7 and RAS-dependent transformation 
The role of HDAC7 in neoplastic transformation is still controversial. Evidences describing 
HDAC7 as an oncogene (Ouaïssi et al., 2014; Zhu et al., 2011) are questioned by other data 
suggesting a role of HDAC7 as a tumour suppressor (Margariti et al., 2010). In 2015 the pro-
growth effect of HDAC7 in epithelial cells was confirmed. In fact, a super-repressive version of 
HDAC7 induced the formation of acini with a higher number of nuclei per acinus in 3D culture 
(Clocchiatti et al., 2015). To better understand the function of HDAC7 in transformed cells and 
its contribution in the neoplastic transformation, we generated MCF10A WT and HDAC7-/- 
expressing HRAS oncogene.  
Interestingly, the expression of RAS increased the expression of HDAC7 in MCF10A-HRAS. Past 
discoveries described a similar effect on HDAC7 expression induced by another oncogene, 
HER2 (Clocchiatti et al., 2015). Furthers analysis will clarify at which level the regulation of 
HDAC7 expression is operated by RAS. Importantly, the RAS transformed phenotype was 
influenced by the HDAC7 expression. This open new hypothesis on the cooperation between 
HDAC7 and oncogenes to promote proliferation, invasiveness and altered morphogenic 
processes. These funding make real the possibility to consider HDAC7 as a carrier of the 
transformed phenotype in malignant cells. Future generation of HDAC7 KO in breast cancer 
cell lines will help to clarify the role of the HDAC7 in breast cancer. 
 
It is well known, in literature, that cancer stem cells are fundamental in the cancer progression 
and relapse after treatment (Chang, 2016; Li et al., 2015). Considering the involvement of 
HDAC7 in stemness, we asked if HDAC7 could be important not only in stem cells but also in 
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cancer stem cells development and self-renewal. Seeding in ULA conditions MCF10A-HRAS 
and MCF10A-HRAS-HDAC7-/- cells, we obtained a small number of spheres. This result 
demonstrates that: a) RAS boosts the proliferative and invasive feature of cells but not the 
stemness proprieties, b) HDAC7 loss impacts on the stemness also in transformed cells.  
In conclusion, our results demonstrate an involvement of HDAC7 in the proliferation of 
mammary epithelial cells. Moreover, it was better investigated the contribution of HDAC7 to 
mammary epithelial stemness and in neoplastic transformation. Certainly, additional steps 
will be important to consolidate the idea of HDAC7 as a therapeutic target in breast cancer. 
Further studies will be necessary to define the HDAC7 role in neoplastic transformation, with 
the aim to generate HDAC7 specific inhibitors for anti-cancer therapy.  
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The MEF2–HDAC axis controls proliferation of mammary
epithelial cells and acini formation in vitro
Andrea Clocchiatti1,*, Eros Di Giorgio1, Giulia Viviani1, Charles Streuli2, Andrea Sgorbissa1, Raffaella Picco1,
Valentina Cutano1 and Claudio Brancolini1,‡
ABSTRACT
The myocyte enhancer factor 2 and histone deacetylase (MEF2–
HDAC) axis is a master regulator of different developmental programs
and adaptive responses in adults. In this paper, we have investigated
the contribution of the axis to the regulation of epithelial
morphogenesis, using 3D organotypic cultures of MCF10A cells as
a model. We have demonstrated that MEF2 transcriptional activity is
upregulated during acini formation, which coincides with exit from the
proliferative phase. Upregulation of the transcription of MEF2 proteins
is coupled to downregulation of HDAC7, which occurs independently
from changes in mRNA levels, and proteasome- or autophagy-
mediated degradation. During acini formation, the MEF2–HDAC axis
contributes to the promotion of cell cycle exit, through the
engagement of the CDK inhibitor CDKN1A. Only in proliferating
cells can HDAC7 bind to the first intron of the CDKN1A gene, a region
characterized by epigenetic markers of active promoters and
enhancers. In cells transformed by the oncogene HER2 (ERBB2),
acini morphogenesis is altered, MEF2 transcription is repressed and
HDAC7 is continuously expressed. Importantly, reactivation of MEF2
transcriptional activity in these cells, through the use of a HER2
inhibitor or by enhancing MEF2 function, corrected the proliferative
defect and re-established normal acini morphogenesis.
KEY WORDS: HDAC7, HDAC4, MEF2A, MEF2D, p21, CDKN1A,
Cell cycle, Morphogenesis, Apoptosis, HDAC5, Breast cancer,
HER2, ERBB2, Lapatinib, 3D culture, H3K27
INTRODUCTION
Mammary morphogenesis is characterized by the presence of
several different instructive signals, which provide the correct
gene expression network to generate the proper glandular
architecture. These structures transit from a disorganized state to
an ordered epithelial organization that modulates polarity,
proliferation and luminal cell clearance (Debnath et al., 2002;
Lewandowski and Piwnica-Worms, 2014). Mammary epithelial
MCF10A cells that have been cultured on a reconstituted
extracellular matrix [three dimensional (3D) culture] undergo a
morphogenetic process that resembles events found in vivo to
generate acinar-like spheroids (Debnath et al., 2002, 2003; Streuli
et al., 1991). Initially, each single cell proliferates to generate a
filled spheroid. During this morphogenetic process, cells of the
outer layer enter G0 (proliferation arrest) and polarize (Debnath
et al., 2002; Weaver et al., 2002; Whyte et al., 2010). The outer
layer of cells that contact the extracellular matrix (ECM) survive,
whereas the inner core of cells, lacking basement membrane
contacts, die through both apoptotic and non-apoptotic processes
(Debnath et al., 2002; Mills et al., 2004; Wang et al., 2003).
Integrin signaling plays a key role at different steps of this
morphogenetic process (Lee and Streuli, 2014; Reginato et al.,
2003), and the absence of integrin-mediated pro-survival signals
(anoikis) promotes the expression and activity of pro-apoptotic
factors. Death of the inner cells is responsible for the formation of
hollow lumen-containing acini.
Transcriptional nodes that are responsible for the genetic
reprogramming that controls this complex morphogenetic process
are not completely defined. The myocyte enhancer factor 2 (MEF2)
family of transcription factors, including the MEF2A, MEF2B,
MEF2C and MEF2D isoforms, plays important functions in tissue
development and homeostasis (Potthoff and Olson, 2007). Genetic
studies in mice have proved the essential contribution of Mef2a to
the regulation of the cardiovascular system (Naya et al., 2002).
Likewise, defects in Mef2c impact on heart development, causing
mice to die at embryonic day (E)9.5 (Lin et al., 1998, 1997). By
contrast, mice with homozygous mutations in Mef2d are viable,
probably because of overlapping expression patterns with other
MEF2 members (Arnold et al., 2007). Conditional cell-lineage-
specific deletions of MEF2s have shown that there are additional
roles for these transcription factors during B-cell development
(Debnath et al., 2013) and bone homeostasis (Collette et al., 2012;
Kramer et al., 2012).
MEF2s influence the expression of numerous genes, depending
on and in cooperation with other transcription factors (Potthoff
and Olson, 2007). They can also operate as transcriptional
repressors, when in complex with class-IIa histone deacetylases
(HDACs) (Gregoire et al., 2006; Lu et al., 2000). HDAC4,
HDAC5, HDAC7 and HDAC9 belong to the class-IIa subfamily,
and they are distinguished by (i) the presence of an N-terminal
regulatory region that is involved in binding to transcription
factors and additional co-repressors, (ii) a C-terminal region that
includes the catalytic domain, which in vertebrates exhibits an
impaired Lys-deacetylase activity and (iii) nuclear–cytoplasmic
shuttling in a signal-responsive fashion (Clocchiatti et al., 2013a,
2011; Yang and Seto, 2008). The intimate relationships between
MEF2s and these repressors support the concept of a MEF2–
HDAC axis.
Deregulated MEF2 transcriptional activities can impact on
tumorigenesis, and recent results have demonstrated alterations in
MEF2 levels and transcription in breast tumors (Clocchiatti et al.,
2013b; Ma et al., 2014; Schuetz et al., 2006). In estrogen receptor
(ER)-positive tumors, repression of putative MEF2-target genesReceived 18 February 2015; Accepted 15 September 2015
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correlates with aggressiveness, and high class-IIa HDAC expression
is associated with reduced survival (Clocchiatti et al., 2013b). By
contrast, in recurrent ER-positive mammary cancers, expression of
MEF2s correlates with NOTCH1 protein levels (Pallavi et al.,
2012). Although some reports point to a contribution of MEF2-
dependent transcription to mammary gland neoplastic pathogenesis,
data on the role of the MEF2–HDAC axis during normal gland
development and homeostasis are lacking, and only little
information is available on the role of the axis in epithelial cells
(Ishikawa et al., 2010). Based on this evidence, we hypothesized
that the MEF2–HDAC axis plays a role in the regulation of breast
epithelial cell proliferation and/or differentiation. In this work, we
have investigated the contribution of the axis to acini
morphogenesis using an experimental model of MCF10A cells
cultured in three dimensions.
RESULTS
Regulation of the MEF2–HDAC axis during acini
morphogenesis
The first indication that the MEF2–HDAC axis contributes to
mammary breast epithelial homeostasis resulted from the
association of MEF2D expression with a better overall survival of
individuals with breast cancer (Fig. 1A). Furthermore, MEF2D
expression was significantly higher in normal samples compared to
that in aggressive grade three cancers (Fig. 1B). Because high grading
is associated with compromised glandular architecture and
differentiation (Elston and Ellis, 2002), we decided to investigate
the contribution of the MEF2–HDAC axis to mammary epithelial
morphogenesis andmaintenance. To gain insight intowhichmembers
are expressed in this context, we compared expressed sequence tag
(EST) profiles between skeletal muscle and breast tissue for class-IIa
HDACs andMEF2A,MEF2C andMEF2D (Fig. 1C). As expected, in
skeletal muscle, MEF2C, HDAC4 and HDAC5 were the most
expressed members of each family. By contrast, in breast tissue,
MEF2A, MEF2D and HDAC7 were the most expressed isoforms.
Furthermore, Gene Set Enrichment Analysis (GSEA), using a
signature of putative MEF2-target genes, suggested that MEF2-
dependent transcription was positively modulated during MCF10A
acinarmorphogenesis (Fig. 1D). Hence, we selectedMCF10A cells to
investigate the role of the MEF2–HDAC axis during epithelial
morphogenesis.When plated onto laminin-richECM(for 3Dculture),
MCF10A cells transited from an initial proliferative disorganized state
(Fig. 1E, day 4), evidenced by the presence of several mitotic figures
per acinus (Fig. 1F) and by the random orientation of the Golgi, to a
quiescent polarized condition, marked by Golgi re-orientation,
formation of a hollow lumen and the absence of mitotic figures
(Fig. 1E, day 16 and 1F).
The bioinformatics analysis prompted us to evaluate the
transcriptional activity of MEF2s during acini development.
Quantitative real-time (qRT)-PCR experiments showed that the
mRNA levels of some MEF2-target genes – KLF2, KLF4, NR4A1,
END1 and RHOB – were augmented, although with different
magnitudes, when acinar morphogenesis was completed at day 16
(Fig. 2A). Together withMEF2-target genes,MEF2DmRNA levels
rose, similar to that described previously during muscle
differentiation (Nebbioso et al., 2009; Sebastian et al., 2013)
(Fig. 2B). The expression of HDAC5 and HDAC9 also increased
during the acinar developmental process, whereas that of HDAC4
and HDAC7 remained constant (Fig. 2B). The upregulation of
CDKN1A was selected as a marker of growth arrest (Besson et al.,
2008), whereas BMF and BIMwere selected as markers of apoptosis
(Mailleux, et al., 2008).
To clarify the apparent paradox of the MEF2-dependent
transcriptional stimulation coupled to the upregulation of HDAC5
andHDAC9mRNA levels, we performed an absolute quantification
of class-IIa HDAC expression (Fig. 2C). This analysis suggested
that, in MCF10A cells, HDAC7 and HDAC4 levels are largely
dominant over those of other class-IIa deacetylases and that,
therefore, even a sixfold increase in HDAC5 mRNA could be
irrelevant in the context of MEF2-dependent transcription. The
immunoblot analysis confirmed the upregulation of MEF2D and
HDAC5 during acini morphogenesis and exposed a dramatic
downregulation of HDAC7 levels (Fig. 2D). This drastic reduction
of HDAC7 could explain the upregulation of MEF2-dependent
transcription. Because HDAC7 downregulation did not result from a
decrease of mRNA levels, to gain insight into the mechanism,
MCF10A cells that had been grown for 4 or 16 days under 3D
culture conditions were treated with bortezomib to block
proteasome-mediated degradation or with chloroquine to block
lysosome- and autophagy-mediated degradation, or with a
combination of both drugs. Although class-IIa proteins can be
targets of the proteasome (Cernotta et al., 2011; Potthoff et al.,
2007), HDAC7 downregulation was unaffected by both drugs
(Fig. 2E), thus indicating that other proteolytic events
or mechanisms control HDAC7 protein levels during acini
formation.
Class-IIa HDAC nuclear–cytoplasmic shuttling is under the
influence of multiple signaling pathways (Clocchiatti et al., 2011).
We therefore investigated the subcellular localization of MEF2D,
HDAC4 (Fig. 2F) and HDAC7 (Fig. 2G) in cells that had been
grown for 4 or 16 days under 3D culture conditions. MEF2D
localized in the nucleus, and both deacetylases showed both nuclear
and cytoplasmic distributions. Treatment of MCF10A cells with
leptomycin-B, an inhibitor of CRM1-mediated nuclear export,
promoted the nuclear accumulation of HDAC7, thus indicating that
the deacetylase undergoes nuclear–cytoplasmic shuttling. Similar
results were observed at day 16 and for HDAC4 (data not shown). In
conclusion, we have demonstrated that the MEF2–HDAC axis is
regulated during acinar morphogenesis and that the upregulation of
MEF2 transcriptional activity could be the consequence of HDAC7
downregulation.
MEF2D downregulation does not affect acinar
morphogenesis but elicits different compensatory
mechanisms
MEF2 transcriptional activities could play roles during acinar
morphogenesis. To comprehend this role, we silenced MEF2D
expression by using lentiviral infection with small hairpin (sh)
RNAs. We selected MEF2D because (i) MEF2D is the most
expressed isoform in breast tissue (Fig. 1A) and (ii) its expression is
upregulated during morphogenesis (Fig. 2B,D). Despite an evident
downregulation of MEF2D at the mRNA and protein levels,
MCF10A cells expressing two different shRNAs against MEF2D
(Fig. S1A,B) did not show any evidence that the expression of the
MEF2-target genes had been negatively altered. Instead,
unexpectedly, END1 mRNA levels were augmented (Fig. S1B).
In cells with downregulated MEF2D, acinar morphogenesis
appeared to be normal, as proved by scoring the luminal filling
per structure and Golgi orientation (Fig. S1C). We also evaluated
whether the absence of MEF2D could influence the initial
proliferation phase by measuring the acinar size. Here, again
MEF2D seemed to be dispensable (Fig. S1D). The absence of
evident phenotypes in cells that had been silenced forMEF2D could
be the consequence of redundancy and/or of compensatory
3962
RESEARCH ARTICLE Journal of Cell Science (2015) 128, 3961-3976 doi:10.1242/jcs.170357
Jo
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
Fig. 1. See next page for legend.
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mechanisms, as observed in other contexts (Liu et al., 2014). In fact,
MCF10A cells with downregulated MEF2D exhibited an increase
in MEF2A protein levels, in concert with HDAC4 and HDAC5
downregulation (Fig. S1A).
Unscheduled expression of MEF2 compromises cell
proliferation and reduces acini size
To understand the contribution of the MEF2–HDAC axis, we
decided to use an alternative strategy. We introduced into MCF10A
cells a conditionally active form of MEF2C fused to the VP16
activation domain of herpes simplex and to the ligand binding
domain of the estrogen receptor (Flavell et al., 2006), as a control, a
DNA-binding defective mutant (ΔDBD) was used (Fig. 3A). In 2D
culture, activation of MEF2–VP16 with 4-hydroxytamoxifen
(4-OHT), but not the control construct, efficiently promoted
transcription of MEF2-target genes (Fig. 3B). Importantly, the
magnitude of induction perfectly mirrored the changes observed
during acini morphogenesis in 3D culture (compare Figs 2B and
3B). Induction of MEF2 transcriptional program in 2D-cultured
MCF10A cells had a profound effect on proliferation (Fig. 3C).
This anti-proliferative effect was also observed when cells were
grown in 3D. Timecourse analysis indicated that stimulation of
MEF2 activity within the first four days constrained acinar size
(Fig. 3D). At day 4, in the presence of unscheduled MEF2
transcriptional activity, acinar structures were smaller and
populated by a reduced number of cells (Fig. 3E and F). To
understand whether MEF2 elicits a growth-repressive effect during
different phases of acinar morphogenesis, we selectively stimulated
its activity for 4 days, starting from day 4, 8 or 12. Boosting MEF2
transcriptional activity from day 4 to day 8 still interfered with the
proliferation of MCF10A cells, as evidenced by the reduced acini
size (Fig. 3G), the number of cells (Fig. 3H) and the dramatic
decrease of mitotic activity (Fig. 3I). It is noteworthy that activation
of MEF2 at the next time intervals (at day 8 or 12) did not exert any
effect on acinar diameter (Fig. 3J and K), cell numbers or luminal
cell death (data not shown), thus indicating that MEF2
perturbations are principally linked to the proliferative phase of
the morphogenetic process. Overall, these data suggest that, in
order to proceed with the normal morphogenetic process in the
mammary epithelial cells, MEF2 transcriptional activity must be
restrained during the initial proliferative phase.
Sustained HDAC7 activity promotes cell proliferation and
affects acinar morphogenesis
The demonstration of a role for MEF2-dependent transcription in
limiting the proliferation of mammary epithelial cells indicates that
the downregulation of HDAC7, which is observed during the
morphogenetic process, could be instrumental to drive the exit
from the cell cycle. To verify this hypothesis, we generated
MCF10A cells expressing a conditionally active form of HDAC7,
fused to the ligand-binding domain of the estrogen receptor
(Fig. 4A). This mutant, named HDAC7/SA-ER, presents the
replacement of four serine residues with alanine residues, in the
amino-terminal region (Dequiedt et al., 2003). In the wild-type
protein, these serine residues, once phosphorylated by various
kinases, become binding sites for 14-3-3 proteins and are required
for the efficient nuclear export of the deacetylase (Yang and Seto,
2008). Hence, upon treatment with 4-OHT, this chimera should
promptly accumulate in the nucleus and repress MEF2-dependent
transcription. Fig. 4A shows that the fused protein is expressed at
the expected size and, after 4-OHT addition, it efficiently
accumulates in the nucleus of MCF10A cells (Fig. 4B).
Moreover, HDAC7/SA-ER effectively repressed MEF2-
dependent transcription, as evidenced by the decrease in RHOB
mRNA levels after 8 days in 3D culture (Fig. 4C). To determine the
effect of unscheduled HDAC7 repressive activity during
morphogenesis, we observed the acinar size at 4, 8 and 12 days
after induction with 4-OHT. Acini that had been generated by
MCF10A cells expressing HDAC7/SA-ER were bigger at all time
points analyzed (Fig. 4D). This increase in size depended on an
increase in the number of nuclei per acinus (Fig. 4E). The increased
number of acini presenting a partially filled lumen (Fig. 4F and the
quantitative analysis in Fig. 4G) confirmed the pro-growth effect of
HDAC7. However, HDAC7/SA-ER acini were also characterized
by higher numbers of picnotic and fragmented nuclei (Fig. 4E,
arrows, and quantitative analysis in Fig. 4H) pointing to an increase
in the apoptotic activity as a counterbalance in order to restrain
excessive proliferation. These data indicate that although HDAC7
can stimulate epithelial cell growth, compensatory mechanisms are
engaged that limit this potentially harmful effect. When the MEF2-
binding sequence (amino acids 78–93) was removed, HDAC7/SA-
ER was incapable of sustaining cell proliferation (Fig. S2A–E).
These results further strengthen the evidence for the importance of
the MEF2–HDAC axis in the control of mammary epithelial cell
proliferation.
MEF2-dependent transcription and HDAC7 levels are
regulated during growth arrest in mammary epithelial cells
The discovery that MEF2 activity influences cell cycle progression
encouraged us to address whether this response can also be
observed independently from the morphogenetic process. As
alternative conditions for G0 induction, exit from the cell cycle
was promoted by density-dependent inhibition and by growth
factor starvation. Under contact inhibition, MEF2A and MEF2D
protein levels increased in the absence of appreciable rises of the
relative mRNAs (Fig. 5A and B). As described above under 3D
culture conditions, HDAC7 protein levels decreased and HDAC5
Fig. 1. TheMEF2–HDACaxis inmammary gland. (A) Kaplan–Meier analysis
based on the expression levels of MEF2D. Data were from 2136 arrays
including 997 for discovery, 995 for validation and 144 of normal breast. The
associated genotype and expression data are deposited at the European
Genome-Phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted
by the European Bioinformatics Institute, under accession number
EGAS00000000083. (B) Box plots illustrating MEF2D mRNA levels in normal
breast and cancer counterparts. Expression levels of MEF2Dwere significantly
reduced in tumor samples and particularly in grade (G)3 tumors. Statistical
significance was calculated using the Wilcoxon rank-sum test. Grade3
discovery vs normal, 3.88×10
−41
; Grade3 validation vs normal, 4.47×10
−41
.
Data were from 2136 arrays including 997 for discovery, 995 for validation and
144 of normal breast. The associated genotype and expression data are
deposited at the European Genome-Phenome Archive (EGA, http://www.ebi.
ac.uk/ega/), which is hosted by the European Bioinformatics Institute, under
accession number EGAS00000000083. Boxes represent the first and the third
quartile, the middle line represents the median, and whiskers represent the
minimum and the maximum. (C) Plots illustrating the frequency of EST tags for
class-IIa HDACs and MEF2-family members in skeletal muscle and breast
tissues. Data were retrieved from http://www.ncbi.nlm.nih.gov/nucest/.
(D) GSEA analysis of a list of 900 putative MEF2-target genes in expression
data fromMCF10A cells cultured under 3D conditions comparing day 8with 16.
Dataset was obtained from GEO (http://www.ncbi.nlm.nih.gov/geo/)
GSE26148 (Simpson et al., 2011). (E) Confocal images comparing MCF10A
cells grown in 3D culture for 4 or 16 days to evaluate the distribution of the Golgi
using the GM130 marker (red) and nuclei (blue) using TOPRO-3. Images are
shown in pseudocolors. Scale bars: 10 µm. (F) Quantification of luminal filling
and mitotic figures in acini generated by MCF10A cells grown in 3D for 4 or
16 days. ***P<0.005 (t-test).
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levels increased (Fig. 5A). Expression of KLF2, RHOB and
HDAC5 augmented, whereas HDAC7 mRNA levels were
unchanged (Fig. 5B). Similar results were obtained when G0 was
elicited through serum and growth factor deprivation (Fig. 5C and
D). Serum starvation triggered the downregulation of HDAC4, as
previously observed (Cernotta et al., 2011). Induction of HDAC7
repressive activity using the HDAC7/SA-ER chimera in cells that
had been subjected to growth factor deprivation limited the
Fig. 2. Analysis of MEF2-dependent transcription and
class-IIa HDAC expression in MCF10A breast
epithelial cells during acini morphogenesis. (A) qRT-
PCR analysis was performed to quantify the mRNA levels
of MEF2-target genes, of the cell cycle inhibitor CDKN1A
and of the apoptotic genes BIM and BMF in MCF10A cells
grown in 3D culture for 4 and 16 days. The fold induction
was calculated as the ratio relative to expression at 4 days
of culture. (B) qRT-PCR was performed to quantify the
mRNA levels of the most abundant class-IIa members
(HDAC4, HDAC5 and HDAC7) as well as of MEF2
members (MEF2A, MEF2C, and MEF2D) in MCF10A
cells grown in 3D for 4 or 16 days. Fold induction was
calculated as the ratio relative to expression at 4 days of
culture. (C) qRT-PCR analysis was performed to quantify
the mRNA levels of all class-IIa members (HDAC4,
HDAC5, HDAC7 and HDAC9) in MCF10A cells. The
expression was calculated as number of copies relative to
the µg of retro-transcribed RNA. (D) Immunoblot analysis
of MEF2-family members and class-IIa HDACs in
MCF10A cells grown in 3D for 4 and 16 days. Cell lysates
of MCF10A cells were subjected to immunoblot analysis
using the indicated antibodies. AKT1 was used as loading
control. (E) Immunoblot analysis of HDAC7 levels in 3D
cultures of MCF10A cells at 4 and 16 days treated or not
with bortezomib or bortezomib in association with
chloroquine for 8 h, as indicated. p53 was used as positive
control for proteasome-mediated degradation inhibition.
p62 and LC3 were used as positive controls for the
blocking of lysosome- and autophagy-mediated
degradation. AKT1 was used as loading control.
(F) Confocal images illustrating the subcellular localization
of MEF2D (red) and HDAC4 (green) in MCF10A cells
grown in 3D culture for 4 and 16 days. Images are shown
in pseudocolors. Scale bars: 10 µm. (G) Confocal pictures
exemplifying the subcellular localization of HDAC7 in
MCF10A cells cultured in 3D for 4 and 16 days, and for
4 days treated or not with leptomycin-B for 1 h. Nuclei
(blue) were stained with TOPRO-3. Images are shown in
pseudocolors. Scale bars: 50 µm. Mean±s.d.; *P<0.05,
**P<0.01, ***P<0.005 (t-test).
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Fig. 3. See next page for legend.
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upregulation of RHOB expression (Fig. S3A), sustained cell
proliferation (Fig. S3B) and DNA synthesis (Fig. S3C). An
increase of cells in S-phase could also be achieved using a
conditionally active mutant form of HDAC4 (Fig. S3B). Compared
to EGF, the HDAC7/SA-ER chimera was less capable of repressing
RHOB and sustaining DNA synthesis. This partial effect could
be a result of the dramatic decrease in its expression that is
observed when cells were deprived of serum and growth factors
(Fig. S3D,E).
The most prominent effect of cell cycle exit on theMEF2–HDAC
axis, in both 3D and 2D culture models, was the downregulation
of HDAC7 levels. To verify whether the upregulation of MEF2-
target genes depends on the reduced recruitment of HDAC7
on the promoter of such genes, we performed chromatin
immunoprecipitation (ChIP) analysis. The RHOB promoter was
selected as a prototype of the MEF2-target genes. Fig. 5E illustrates
that HDAC7 bound to the RHOB proximal promoter during the
proliferative phase, whereas this binding was clearly reduced upon
growth arrest, as induced by either serum starvation or density-
dependent inhibition.
HDAC7 binds to the p21 promoter
Cyclin-dependent kinases (CDKs) are master regulators of cell
cycle progression and cell proliferation. The CDK inhibitor p21
(CDKN1A) is a well-known negative regulator of proliferation,
under the control of multiple signals, including growth factors and
differentiation (Besson et al., 2008). Some reports have suggested
that class-IIa HDACs are involved in the regulation of transcription
of CDKN1A (Liu et al., 2009; Mottet et al., 2009; Wilson et al.,
2008). To explore whether MEF2s and class-IIa HDACs control
p21 expression during acinar morphogenesis, we initially
interrogated the ENCODE database to map the epigenetic status
of the CDKN1A promoter in human mammary epithelial cells
(HMECs) (Ernst et al., 2011; Rosenbloom et al., 2013). We
investigated the genomic region that is situated between two
insulators (CTCF). Trimethylated Lys4 of histone 3 (H3K4me3)
and acetylated Lys27 of histone 3 (H3K27ac), well-known markers
of open chromatin status and characteristics of active promoter and
enhancer regions, outline the first intron as an important element
that is involved in CDKN1A transcription (Fig. 6A). A similar
pattern can be observed in lymphoblastoid GM12878 cells (Fig. S4)
and in the leukemia cells K562 (data not shown). Interestingly, the
available ENCODE data for GM12878 and K562 cell lines
highlighted the conserved binding of MEF2 factors to the
promoter and enhancer elements, although with slight variations
in the position of binding.
Next we screened for potential MEF2-binding sites a 20-kb
genomic region of CDKN1A, comprising the first intron, which
contains the active chromatin markers above described. The
enlargement in Fig. 6A illustrates the presence of several potential
MEF2 binding sites in the analyzed genomic region and particularly
in the first intron.
To evaluate the involvement of HDAC7 in the regulation of
CDKN1A transcription, we decided to investigate its ability to bind
to the regions highlighted in Fig. 6A. ChIP experiments proved that
HDAC7 bound preferentially to the region containing the MEF2-
binding site at +1.5 kb from the transcription start site (TSS).
Importantly, this binding was abolished or dramatically reduced
when growth arrest was induced by growth factor starvation or high
confluence (Fig. 6B).
Class-IIa HDACs are recruited to specific genomic regions
following interactions with DNA-binding transcription factors.
Hence, we assessed the binding of MEF2D to the same genomic
regions. In proliferating cells, MEF2D bound to the RHOB and the
CDKN1A promoters at +1.5 and +2.1 kb from the TSS, respectively
(Fig. 7A). Surprisingly, a different behavior was observed in starved
cells in contrast to confluent cells. MEF2D binding was maintained
under starvation on both promoters in the same regions (slightly
increased in the case of CDKN1A), whereas it was dramatically
decreased in confluent cells. For CDKN1A, a new binding of
MEF2D at the −5.7 kb region was observed only when cells were
arrested through confluence.
ChIP experiments using an antibody against H3K27ac
(Fig. 7B) confirmed the ENCODE data. Enrichment for H3K27
acetylation could be observed from +1.5 kb up to +3.6 kb from
the TSS of the CDKN1A promoter (compare Fig. 6A).
Concerning RHOB, H3K27ac was not pronounced, probably
because this region is very close to the TSS, as reported in the
ENCODE project. Under starvation, a consistent increase in
H3K27ac was observed for the RHOB promoter, and this increase
was much less pronounced at confluence. Overall, changes in this
epigenetic modification are in agreement with MEF2D and
HDAC7 binding to promoters.
Growth arrest through starvation elicits an overt increase of
H3K27ac around the +2.1-kb region of the CDKN1A promoter.
A small but significant increase can be appreciated also in the region
+1.5 kb, in accordance with MEF2D binding and HDAC7 release.
When growth arrest was induced through high confluence, the most
Fig. 3. MEF2 transcriptional activity can compromise cell proliferation
and acini size during the normal morphogenetic process in mammary
epithelial cells. (A) Immunoblot analysis of MEF2-VP16-ER levels in MCF10A
cells expressing the MEF2-VP16-ER chimera (WT) or its mutant that was
defective in DNA binding MEF2ΔDBD-VP16-ER (ΔDBD). MEF2-VP16-ER-
dependent transcription was induced by treating cells with 4-OHT for 24 h. Cell
lysates were generated and subjected to immunoblot analysis with an antibody
against VP16. p120 (also known as CTNND1) was used as a loading control.
(B) mRNA levels of selectedMEF2-target genes weremeasured by using qRT-
PCR analysis of MCF10A cells expressing MEF2-VP16-ER or the mutant
MEF2ΔDBD-VP16-ER following 4-OHT treatment in 2D culture.
(C) Quantitative analysis of cell proliferation of MCF10A cells expressing the
two MEF2 constructs. The day after seeding, 4-OHT was added to the culture
medium, and cell numbers scored 24 h later. (D) Time-course analysis of
acinar area at the indicated times, as generated by MCF10A cells expressing
the twoMEF2 inducible constructs. The dayafter seeding, 4-OHTwas added to
the culture medium. (E) The acinar size of MCF10A cells, expressing the two
MEF2 chimeras, grown in 3D culture for 4 days was analyzed. The day after
seeding, 4-OHT was added to the culture medium. Data are from a
representative set of three independent experiments in which ∼250 acini per
condition were measured. (F) Number of nuclei per acinus as generated by the
different transgenic MCF10A cells after 4 days in 3D culture. (G) The acinar
size of MCF10A cells, expressing the twoMEF2 chimeras, grown 3D culture for
8 days were analyzed. On the fourth day in culture, 4-OHTwas added to culture
medium. Data are from a representative set of three independent experiments
in which ∼250 acini per condition were measured. (H) Number of nuclei per
acinus generated from the different transgenic MCF10A cells after 8 days in 3D
culture. (I) Number of acini with mitotic figures, as generated by the different
transgenic MCF10A cells after 8 days in 3D culture. (J) Acinar size of MCF10A
cells, expressing the two MEF2 inducible constructs, in 3D culture for 12 days
were analyzed. 4-OHT was added to culture medium as indicated. Data are
from a representative set of three independent experiments in which∼250 acini
per condition were measured. (K) The acinar size of MCF10A cells, expressing
the two MEF2 inducible constructs, in 3D culture for 16 days were analyzed.
4-OHT was added to culture medium as indicated. Data are from a
representative set of three independent experiments in which ∼250 acini per
condition were measured. E,G,J,K, boxes represents the first and the third
quartile, the middle line represents the median, whiskers represent the 10th
and the 90th percentile, and dots represents the outliers. Mean±s.d.;
***P<0.005, ****P<0.001 (Mann–Whitney test).
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evident relative increase in H3K27ac regarded the overall poorly
acetylated region at −5.7 kb. This is the same region bound by
MEF2D in confluent cells (Fig. 7A).
The involvement of the MEF2–HDAC axis in the regulation of
CDKN1A transcription was confirmed after induction of the MEF2-
VP16 chimera in 2D conditions at both mRNA and protein levels
Fig. 4. Sustained HDAC7 activity promotes cell proliferation and affects acinarmorphogenesis. (A) Immunoblot analysis of HDAC7 levels in MCF10A cells
expressing a mutant form of HDAC7 in which four serine residues were mutated (normally the binding sites for 14-3-3 proteins) (HDAC7/SA-ER) or the control
empty vector. HDAC7/SA-ER activity was induced by treating cells with 4-OHT for 24 h. Cellular lysates were generated and subjected to immunoblot analysis to
verify the molecular size of the transgene using an anti-HDAC7 antibody. AKT1 was used as a loading control. (B) Confocal pictures of MCF10A cells showing
HDAC7/SA-ER nuclear accumulation after the induction with 4-OHT. Nuclei were stained with TOPRO-3. Images are shown in pseudocolors. (C) mRNA
expression levels of theMEF2-target geneRHOBweremeasured byusing qRT-PCRanalysis ofMCF10Acells expressingHDAC7/SA-ERorcontrol cells grown in
3Dculture for 8 days. 4-OHTwasadded to culturemediumon the dayof seeding and the fourth dayof culture. (D) Acinar size ofMCF10A cells, expressingHDAC7/
SA-ER, in 3D culture for 4, 8 and 12 days. When cells were seeded, 4-OHTwas added to culture medium as well as on every fourth day in culture. Data are from a
representative set of three independent experiments in which∼250 acini per condition weremeasured. Boxes represents the first and the third quartile, the middle
line represents the median, whiskers represent the 10th and the 90th percentile, and dots represents the outliers. (E) Number of nuclei per acinus, as generated
from MCF10A cells expressing HDAC7/SA-ER or the control, after 12 days in 3D culture. (F) Confocal images comparing the presence of picnotic fragmented
apoptotic nuclei in the lumen of acini generated fromMCF10A cells, expressing HDAC7/SA-ERor the control, grown in 3D culture for 12 days. Nuclei were stained
with Hoechst 33258. Images are shown in pseudocolors. Arrowheads point to picnotic apoptotic nuclei. (G) Quantification of the number of acini with normal nuclei
in the lumen, as generated by MCF10A expressing the different transgenes after 12 days of culture in 3D. (H) Quantification of the number of apoptotic cells per
acini, as generated by MCF10A expressing the different transgenes after 12 days in 3D culture. Mean±s.d.; *P<0.05, **P<0.01, ***P<0.005, ****P<0.001 (t-test).
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(Fig. 7C,D), and in 3D conditions at the mRNA level (Fig. 7E).
Finally, the repression that was mediated by the HDAC7/SA-ER
chimera in 2D (Fig. S2F) and 3D conditions (Fig. 7F) further
supports such involvement.
The MEF2–HDAC axis is regulated during HER2-mediated
transformation of mammary epithelial cells
The contribution of the MEF2–HDAC axis to the regulation of
mammary epithelial cell proliferation prompted us to determine
whether oncogenic lesions that alter mammary epithelial
morphogenesis provoke dysregulation of the axis. The tyrosine
kinase receptor HER2 (also known as ERBB2) is the key
determinant of a subclass of breast tumors, and overexpression of
HER2 profoundly alters the normal mammary epithelial
morphogenetic process (Leung and Brugge, 2012). Hence, we
generated MCF10A cells that overexpressed HER2 to assess
dysregulation of the MEF2–HDAC axis. After 16 days in 3D
culture, HER2-overexpressing cells showed an elevated
proliferative index, as proved by the development of larger acini
(Fig. 8A) that comprised higher numbers of cells per structure and
that were marked by the presence of mitotic figures even at day 16
(Fig. 8B). Moreover, the compromised epithelial organization was
apparent because of the alterations in polarity and the presence
of cells in the luminal cavity (Fig. 8B). Accordingly, HER2
significantly reduced the expression of epithelial morphogenesis
markers (BIM and BMF). Similarly, the expression of certain MEF2
targets (KLF2, RHOB and CDKN1A) was reduced (Fig. 8C).
Importantly, the decrease in MEF2-dependent transcription was
coupled to the rescue of HDAC7 levels at day 16 (Fig. 8D).
Curiously, MEF2D levels seem to increase in HER2-expressing
cells. Conversely, the inhibition of HER2 tyrosine kinase activity
with lapatinib, a quinazoline derivative, dramatically impacted on
epithelial growth, thus limiting acinar size (Fig. 8E). Acinar
cellularity and mitotic figures were also reduced in lapatinib-treated
cells (Fig. 8F). Lapatinib also restored the appearance of acini with
hollow lumens (Fig. 8F). Interestingly, the effect of this inhibitor
seemed to be cell cycle dependent, without interference through the
induction of apoptosis, as supported by the unchanged rate of
picnotic nuclei per acini (Fig. 8F).
In agreement with our studies, treatment of MCF10A HER2-
expressing cells that had been grown for 8 days in 3D culture with
lapatinib upregulated MEF2-dependent gene transcription, the
expression of BIM and BMF morphogenetic markers (Fig. 8G)
and elicited the downregulation of HDAC7 (Fig. 8H). HDAC7
downregulation showed the same features during growth arrest as
described above. It occurred in the absence of changes in mRNA
levels (Fig. 8G) and was lysosome and proteasome independent
(Fig. S4C). Interestingly, HDAC4 levels seemed to be reduced after
HER2 inhibition.
Importantly, induction of MEF2 transcription in MCF10A cells
that expressed HER2 restored normal epithelial morphogenesis to
an extent that was comparable to that with lapatinib. All of the
proliferative parameters (average number of nuclei per acinus, the
percentage of acini with mitotic figures and of acini with normal
nuclei in the lumen) were reduced following MEF2 activation in
HER2-overexpressing cells (Fig. 8I).
DISCUSSION
The mammary gland undergoes complex remodeling during
different stages – i.e. puberty, pregnancy, lactation and involution
(Gjorevski and Nelson, 2011). 3D cultures have significantly helped
in understanding how some of these processes take place.
Fig. 5. MEF2-dependent transcription and HDAC7 levels are regulated
during growth arrest in mammary epithelial cells. (A) Immunoblot analysis
of MEFs and class-IIa HDAC-family member levels in MCF10A cells. Cellular
lysates were obtained at the indicated time points after seeding in complete
medium and subjected to immunoblot analysis using the specific antibodies.
AKT1 was used as loading control. Cell cycle analysis is provided underneath
the blots as percentage of cells. (B) qRT-PCR analysis was performed to
quantify mRNA levels of class-IIa members (HDAC4,HDAC5 andHDAC7) and
of MEF2s (MEF2A and MEF2D), as well as of MEF2-taget genes (KLF2 and
RHOB) in MCF10A cells. The fold induction was calculated as the ratio relative
to expression at 1 day of culture in complete medium. Data are from three
independent experiments. (C) Immunoblot analysis of MEF2- and class-IIa-
HDAC-family member levels in MCF10A cells. Cellular lysates were obtained at
the different growing conditions and subjected to immunoblot analysis using the
specific antibodies. AKT1 was used as loading control. Cell cycle analysis is
provided underneath the blots as percentage of cells. (D) qRT-PCR analysis
was performed to quantify the mRNA levels of the most expressed class-IIa
members (HDAC4,HDAC5 andHDAC7) aswell as of MEF2members (MEF2A
andMEF2D) and MEF2-target genes (KLF2 andRHOB) in MCF10A cells. Fold
induction was calculated as the ratio between starvation and growing
conditions. Data are from three independent experiments. (E) qRT-PCR
analysis on chromatin that had been immunoprecipitated with the indicated
antibodies in the different conditions shown. Mean±s.d.; *P<0.05, **P<0.01,
***P<0.005 (one-way ANOVA test coupled to Tukey’s HSD post-hoc test).
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Particularly, althoughMCF10A cells grown under 3D conditions do
not enter terminal differentiation (Muthuswamy et al., 2001) with
milk protein production, the imposed 3D environment influences
cell behavior and mimics the steps required for proper
developmental and homeostatic cues (Leung and Brugge, 2012;
Lo et al., 2012; Shaw et al., 2004). Complex cellular decisions take
place during the 16-day interval that is necessary for acini
formation. After the initial proliferation phase, cells begin to
polarize and gradually exit from the cell cycle. The process
terminates with the death of the cells in the lumen and with cavity
formation (Frisch et al., 2013).
In this context, we have studied the regulation of the MEF2–
HDAC axis and have dissected its contribution to the epithelial
morphogenetic program. Quantitative and qualitative changes in
gene expression profiles characterize the morphogenetic process
of MCF10A cells grown under 3D condition (Yu et al., 2012).
However, few studies have addressed the contribution of specific
transcription factors and of the relative transcriptional gene
networks to this morphogenetic process. We have initially
demonstrated that the expression of MEF2-target genes is
augmented during acini formation. This behavior resembles that
under other differentiation contexts, as in skeletal muscle, where the
contribution of the axis has been previously studied (McKinsey
et al., 2000; Sebastian et al., 2013). Activation of MEF2
transcription is parallel to a dramatic downregulation of HDAC7
protein. In MCF10A cells, in contrast to other cellular models, anti-
proliferative signals unleash MEF2-dependent transcription by
impacting on HDAC7 levels, rather than by controlling its nuclear–
cytoplasmic shuttling (McKinsey et al., 2000; Paroni et al., 2008).
HDAC7 downregulation is linked to growth arrest, and it can also be
observed in 2D conditions, after growth factor starvation or density
inhibition. At the moment, the mechanism that is responsible for
HDAC7 downregulation is unknown. We can only exclude changes
in mRNA levels, in proteasomal degradation and in autophagy.
HDAC5 and HDAC9 expression increases during acini
formation. Being both MEF2-target genes, it is possible that such
induction is part of the well-known negative feedback loop that is
activated by MEF2 itself (Haberland et al., 2007). Nevertheless,
because HDAC7 is the most expressed class-IIa deacetylase in
breast tissue and in MCF10A cells, its withdrawal can justify the
upregulation of MEF2 transcription. Furthermore, some reports
indicate a differential repressive capability of class-IIa HDACs
towards MEF2 proteins, with HDAC5 being the enzyme that is least
prone to such repression (Dressel et al., 2001).
Fig. 6. HDAC7 binds to the promoter region of
CDKN1A. (A) Schematic representation of the
epigenetic status of the CDKN1A locus in human
mammary epithelial cells as mapped with the ENCODE
project. Two insulator CTCF peaks comprise the
analyzed region, and the promoter was identified
through H3K4me3 and H3K27ac signals. A region of
20 kb, highlighted in the black box, including the
promoter, was selected and scanned for putative MEF2-
binding sites. (B) qRT-PCR analysis on chromatin
immunoprecipitated with the indicated antibodies in
different growth conditions as shown. The different
genomic regions of CDKN1A containing putative MEF2-
binding sites are indicated starting from the transcription
start site. An internal region (+4.7 kb) of the CDKN1A
gene was used as a negative control (Control). Mean±
s.e.m.; *P<0.05 (one-way ANOVA test coupled to
Tukey’s HSD post-hoc test).
3970
RESEARCH ARTICLE Journal of Cell Science (2015) 128, 3961-3976 doi:10.1242/jcs.170357
Jo
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
We exploited different approaches to interfere with the MEF2
transcriptional activity. In all instances, the effect was an
impediment of the proliferative phase. Increasing MEF2-
dependent transcription reduced cell division, whereas increasing
HDAC7 repressive activity favored cell proliferation. The
polarization process and the induction of cell death were
unaffected after modulation of the MEF2–HDAC axis.
Although MEF2 proteins are the best-characterized class-IIa
HDAC partners, these deacetylases can influence the activity of
additional transcriptional regulators (Clocchiatti et al., 2103a). In
this study, we have found logical correlations between MEF2 and
class-IIa HDACs in the regulation of proliferation and gene
expression during acini formation. Furthermore, deletion of the
MEF2-binding sequence abrogated the pro-growth effect of
Fig. 7. MEF2D binding and H3K27 acetylation at the
promoter regions ofCDKN1A andRHOB. (A) qRT-PCR
analysis on chromatin immunoprecipitated with the
indicated antibodies in the different growth conditions
shown. The different genomic regions of CDKN1A
containing putative MEF2-binding sites are indicated,
starting from the transcription start site. An internal region
(+4.7 kb) of the CDKN1A gene was used as a negative
control (Control). (B) qRT-PCR analysis on chromatin
immunoprecipitated with the indicated antibodies in the
different growth conditions shown. The different genomic
regions of CDKN1A containing putative MEF2-binding
sites are indicated starting from the transcription start site.
An internal region (+4.7 kb) of the CDKN1A gene was
used as a negative control (Control). (C) qRT-PCR
analysis was performed to quantify CDKN1A mRNA
levels in cells in which MEF2 transcription had been
induced after treatment with 4-OHT. Fold induction was
calculated as the ratio relative to expression in cells in
which the expression of MEF2 defective in DNA (ΔDBD)
binding was induced by 4-OHT treatment, as indicated.
(D) Immunoblot analysis of MCF10A cells expressing the
indicated transgene for p21/CDKN1A levels. Induction of
the transgenes was performed as described in
C. (E) mRNA expression levels of CDKN1A were
measured by using qRT-PCR analysis in MCF10A cells
grown for 8 days in 3D culture. MEF2 transcription was
induced after treatment with 4-OHT. The fold induction
was calculated as the ratio of expression relative to that of
cells expressing MEF2 defective in DNA binding. 4-OHT
was added to the culture medium on the day of seeding
and on the fourth day of culture. (F) mRNA expression
levels of CDKN1A were measured by using qRT-PCR in
MCF10A cells expressing HDAC7/SA-ER or the control
construct that had been grown in 3D culture for 8 days.
4-OHT was added to the culture medium the day of
seeding and on the fourth day of culture. WT, non-mutated
construct. Mean±s.e.m.; *P<0.05, **P<0.01, ***P<0.005
(t-test, and one-way ANOVA test coupled to Tukey’s HSD
post-hoc test in B).
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Fig. 8. See next page for legend.
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the nuclear resident HDAC7. Overall, our data strongly support that
the described HDAC7 action is explicated through MEF2s.
We propose that the influence of the axis on cell proliferation
could be operated through the regulation of the CDK inhibitor p21/
CDKN1A. Previous results have shown that class-IIa HDACs can
control CDKN1A expression (Liu et al., 2009; Mottet et al., 2009;
Saramaki et al., 2009; Wilson et al., 2008); however, the
mechanisms involved are debated. MEF2-binding sites are present
in the genomic regions surrounding CDKN1A. In particular, several
MEF2-binding sites lie within the first intron. This intron is
characterized by the presence of open chromatin markers (Ernst
et al., 2011). Our results suggest that the MEF2–HDAC axis
imposes a control on the cell cycle by modulating CDKN1A
expression. Recruitment of HDAC7 onto the CDKN1A promoter
is confined in a region (+1.5 kb) that is also under the control
of MEF2 factors in other cell lineages scrutinized by the ENCODE
project (Ernst et al., 2011). We have also proved that, in MCF10A
cells, MEF2D binds to this region. However, MEF2D can
also tether to additional regions, such as that at +2.1 kb, which are
not bound by HDAC7, as we have recently observed in fibroblasts
(Di Giorgio et al., 2015b). Whether specific MEF2–HDAC
complexes exist bound to different chromatin regions deserves
further studies.
At the +1.5 kb position, HDAC7 binding is dramatically reduced
under conditions that stimulate cell cycle arrest, and this reduction is
associated only with a modest increase in H3K27ac. Even though
class-IIa HDACs do not exhibit catalytic activity, they can act as
platforms to recruit class-I enzymes (Lahm et al., 2007; Di Giorgio
et al., 2015a). Hence, HDAC7 could influence epigenetic changes
at the CDKN1A promoter both by recruiting co-repressors and
by competing with co-activators for binding to MEF2 proteins.
Certainly, it is possible that different growth conditions influence
additional epigenetic changes within this genomic region.
Themost evident increase in H3K27ac was observed as occurring
at the +2.1 kb position when growth arrest was induced by
starvation, pointing to the existence of additional mechanisms of
regulation. Finally, our analysis of the binding of MEF2D to the
CDKN1A promoter indicates the existence of specific chromatin
changes in response to different conditions of growth arrest.
The effect of MEF2 on the regulation of CDKN1A transcription
seems to be a general phenomenon that is not limited to MCF10A
cells. Also, in fibroblasts, MEF2C and MEF2D bind to the
CDKN1A promoter. Importantly, in these cells, the downregulation
of MEF2D is sufficient to increase cell proliferation and efficiently
impacts on the expression of MEF2-target genes, including
CDKN1A (Di Giorgio et al., 2015b).
HER2 overexpression, a frequent oncogenic event in breast
tumors, is able to maintain HDAC7 levels and decrease MEF2
transcription during the morphogenetic process, which might be an
additional and powerful way to control p21 function beyond
regulating its localization (Xia et al., 2004). Interestingly, forcing
MEF2 activity in MCF10A HER2-overexpressing cells reverses the
transformed phenotype, mainly by restraining proliferation, thus
ensuring correct epithelial organization. Furthermore, treatment
with the receptor tyrosine kinase (RTK) inhibitor lapatinib rescued
HDAC7 downregulation and acini formation in 3D cultured cells. In
conclusion, our studies unveil a role for the MEF2–HDAC axis in
the control of epithelial cell proliferation and suggest that targeting
class-IIa HDACs with inhibitors could be an interesting therapeutic
strategy, in addition to or in combination with treatment with RTK
inhibitors, for the treatment of breast cancer.
MATERIALS AND METHODS
Cell culture and reagents
Human normal immortalized epithelial breast cells (MCF10A) (Whyte et al.,
2010) and MCF10A cells expressing HER2 were maintained in Ham’s F12:
Dulbecco’s modified Eagle’s medium (DMEM) 1:1 medium (Sigma-
Aldrich) supplemented with 5% horse serum (Gibco), penicillin (100 U/
ml), streptomycin (100 µg/ml), L-glutamine (2 mM) (Lonza), insulin
(0.01 mg/ml), hydrocortisone (500 ng/ml), cholera toxin (100 ng/ml)
(Sigma-Aldrich) and epithelial growth factor (20 ng/ml) (Peprotech). HEK-
293T cells were grown inDMEMsupplementedwith 10% fetal bovine serum
(FBS), L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 µg/
ml) (Lonza). Cells expressing inducible forms of MEF2 and HDAC7 were
grown in complete F12/DMEMmediumwithout phenol red (Sigma-Aldrich)
and with 5% charcoal-stripped horse serum. The proteasome inhibitor
bortezomib (LC Laboratories) was used at 250 nM for 8 h. The lysosome and
autophagy inhibitor chloroquine (Sigma-Aldrich) was used at 10 µM for 8 h.
The CRM1 inhibitor leptomycin-B (LC Laboratories) was used at 5 ng/ml.
4-OHT (Sigma-Aldrich) was used at 1 µM. The inhibitor of HER2 lapatinib
(LC Laboratories) was used at 1 µM for 2 h.
3D morphogenetic assay
3D morphogenetic assays were conducted as previously described (Debnath
et al., 2003). Briefly, to obtain mammospheres, cells (3×104) were plated in a
thick layer of ∼1–2 mm of laminin-rich extracellular matrix (Cultrex-
Trevigen), under these conditions each acinus derives from a single cell.
Cultrex was overlaid with cells grown in medium containing 5 ng/ml EGF
along with 2% (v/v) cultrex. Cells were maintained at 37°C and 5% CO2 and
the culturemediumwas changed every 4 days. Images ofmammosphereswere
collected byusing aLeicaAF6000LXmicroscope.Acinar areameasurements
were determined using Volocity 3D image analysis software.
Fig. 8. The MEF2–HDAC axis is regulated during HER2-mediated
transformation of mammary epithelial cells. (A) The acinar size of MCF10A
cells expressing HER2 that had been grown in 3D culture for 16 days was
analyzed. Data are from three independent experiments in which ∼250 acini
per condition were measured. (B) The number of nuclei per acinus, number of
acini with normal nuclei in the lumen, number of acini with mitotic figures and
number of polarized acini in acini generated from MCF10A cells expressing
HER2 after 16 days in 3D culture. Puro, indicates the cells that express the
resistence to Puromycin as control. (C) qRT-PCR analysis was performed to
evaluate mRNA levels of MEF2-target genes in MCF10A cells expressing
HER2 that had been cultured in 3D for 16 days. (D) Immunoblot analysis of
MEF2s and class-IIa-HDAC-family member levels in MCF10A cells expressing
HER2 that had been grown in 3D for 16 days. Cell lysates were subjected to
immunoblot analysis using the indicated antibodies. AKT1 was used as
loading control. (E) The acinar size of MCF10A cells expressing HER2 that had
been grown in 3D culture for 16 days and treated or not with lapatinib was
analyzed. Data are from three independent experiments in which ∼250 acini
per condition were measured. (F) The number of nuclei per acinus, number of
acini with normal nuclei in the lumen, number of acini with picnotic and
fragmented apoptotic nuclei and number of acini with mitotic figures in acini
generated from MCF10A cells expressing HER2 that had been treated or not
with lapatinib, after 16 days in 3D culture. (G) qRT-PCR analysis was
performed to evaluate themRNA levels of MEF2-target genes inMCF10A cells
expressing HER2 that had been treated or not with lapatinib and cultured in 3D
for 8 days. (H) Immunoblot analysis of MEFs and class-IIa-HDAC-family
member levels in MCF10A cells expressing HER2 that had been treated or not
with lapatinib and grown in 2D culture. Cell lysates were subjected to
immunoblot analysis using the indicated antibodies. Total ERK1/2 was used as
loading control. (I) The number of nuclei per acinus, number of acini with
picnotic and fragmented apoptotic nuclei, number of acini with mitotic figures
and number of acini with normal nuclei in the lumen in acini generated from
MCF10A cells expressing HER2 and the MEF2-VP16-ER chimera (WT) or its
mutant defective in DNA binding (MEF2ΔDBD-VP16-ER, ΔDBD) after 8 days
in 3D culture. MEF2-VP16-ER activation was induced by adding 4-OHT to
growth medium after 4 days in 3D culture. A,E, Boxes represent the first and
the third quartile, themiddle line represents themedian, whiskers represent the
10th and the 90th percentile, and dots represent the outliers. Mean±s.d.;
*P<0.05, **P<0.01, ***P<0.005, ****P<0.001, Mann–Whitney test.
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Plasmid construction, transfection, retroviral and lentiviral
infection, and silencing
The pWZL-Hygro-MEF2C-VP16-ER construct comprising the first 119
amino acids ofMEF2Chas beenpreviously described (DiGiorgio et al., 2013).
The ligand-binding domain of the estrogen receptor was PCR amplified from
pcDNA MEF2-VP16-ER (Flavell et al., 2006) and cloned into pWZLHygro.
Togenerate pWZL-Hygro-HDAC7/SA-ER, anEcoRI-digested fragment of the
HDAC7/SA point mutant (Di Giorgio et al., 2013) was cloned into pWZL-
Hygro-ER.MCF10Acells expressing theMEF2-VP16-ERorHDAC7/SA-ER
transgeneswere generated byusing retroviral infection, as described previously
(Cernotta et al., 2011). The HDAC7/SA-ER construct that comprised deletion
of the MEF2-binding domain, lacking amino acids 78–93 was generated by
using PCR and subsequent two steps cloning into pWZL-Hygro-ER. HEK-
293T packaging cells were transfected 24 h after plating by using calcium-
phosphate precipitation. After 48–72 h, the virus-containing medium was
filtered and added to target cells. Recombinant lentiviruses (Sigma-Aldrich)
were produced through transfection of HEK-293T cells. Briefly, subconfluent
HEK-293T packaging cells were co-transfected with 20 µg of lentiviral vector
plasmids, 15 µg of pCMV-ΔR8.91 and 5 µg of VSVG envelope plasmid by
using calcium-phosphate precipitation. After 24 h, medium was changed, and
recombinant lentiviruses vectors were harvested 24–36 h later.
Immunofluorescence, antibody production and immunoblotting
Cells were fixed in 3% paraformaldehyde and permeabilized with 1%
Triton-X100. Next, coverslips were incubated with the following primary
antibodies: anti-HDAC4 (Paroni et al., 2004), anti-HDAC7 (sc-74563;
Santa Cruz Biotechnology), anti-MEF2D (610774; BD Transduction
Laboratories) and anti-GM130 (610822; BD Transduction Laboratories).
Then, they were incubated with 488- or 546-Alexa-Fluor-conjugated
secondary antibodies (Life Technologies). Finally, coverslips were
incubated for 15 min with 5 µM TOPRO-3 (610822; Life Technologies)
to label nuclei. Cells were imaged with a Leica confocal scanner SP
instrument that was equipped with a 488-λ argon laser and a 543–633-λ
helium-neon laser. Representative confocal images are shown as equatorial
cross sections through the middle of acini.
Rabbits were immunized with a recombinant histidine-tagged HDAC5
fragment (amino acids 1132–2040) that had been purified from Escherichia
coli. For purification of the anti-HDAC5 antibody from antiserum, HDAC5
was fused to glutathione S-transferase (GST) and cross-linked to
glutathione–Sepharose, as described previously (Paroni et al., 2001).
Cell lysates after SDS-PAGE and immunoblotting were incubated with the
following primary antibodies against: HDAC4 (Paroni et al., 2004), HDAC7
(sc-74563; Santa Cruz Biotechnology), MEF2A (sc-10794; Santa Cruz
Biotechnology), MEF2D (610774; BD Transduction Laboratories), AKT
(#9272; Cell Signaling Technology), p53 (sc-126; Santa Cruz
Biotechnology), p62 (610497; BD Transduction Laboratories), LC3
(Demarchi et al., 2006), VP16 (sc-7545; Santa Cruz Biotechnology), p120
(610134; BD Transduction Laboratories), ERK (#4695; Cell Signaling
Technology), phosphorylated ERK (#9101; Cell Signaling Technology).
Secondary antibodies were obtained from Sigma-Aldrich, and blots were
developed with Super West Dura (Pierce). To strip antibodies, blots were
incubated for 30 min at 60°C in stripping solution containing 100 mM
β-mercaptoethanol. DNA staining was performed as described previously
(Cernotta et al., 2011). For S-phase analysis, cells were grown for 3 h with
100 μM bromodeoxyuridine (BrdU). After fixation, coverslips were treated
with 1 N HCl (10 min, in ice), followed by 20 min with 2 N HCl at room
temperature. Mouse anti-BrdU (B8434; Sigma-Aldrich) was used as primary
antibody. Nuclei were stained with Hoechst 33258 (Sigma-Aldrich).
RNA extraction and qRT-PCR
Cells were lysed using RiboEx (GeneAll Biotechnology). 1 µg of total RNA
was retro-transcribed by using 100 units of M-MLV reverse transcriptase
(Life Technologies). qRT-PCR analyses were performed using the Bio-Rad
CFX96 apparatus and SYBR Green technology (Kapa). Data were analyzed
with the ΔΔCt method, using glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) and hypoxanthine phosphor-ribosyltransferase (HPRT) as
normalizer genes. All reactions were performed in triplicate. To evaluate
the mRNA copies per µg of retro-transcribed RNA for each class-IIa HDAC,
standard curves of the qRT-PCR amplification were obtained using defined
concentrations of the relative cDNAs.
Chromatin immunoprecipitation
For immunoprecipitations, DNA–protein complexes were cross-linked with
1% formaldehyde (Sigma-Aldrich) in PBS for 15 min at room temperature.
After quenching and twowashes in PBS, cells were collected and then lysed
for 10 min with lysis buffer (5 mM PIPES, 85 mM KCl, 0.5% NP-40)
containing protease inhibitor cocktail (Sigma-Aldrich). The pellets were re-
suspended in RIPA-100 and sonicated using Bioruptor UCD-200
(Diagenode) with pulses of 30 s for 15 min, resulting in an average size
of ∼500 bp for genomic DNA fragments. Samples were pre-cleared and
immunoprecipitated overnight with 1 µg of anti-HDAC7 (sc-74563, Santa
Cruz Biotechnology), 1.5 µM of anti-H3K27Ac (ab4729; Abcam) and
2 µM of anti-MEF2D antibodies followed by incubation with protein-A
beads (GE Healthcare Bio-Sciences) blocked with BSA and salmon sperm
DNA (1 µg/µl) at 4°C for 2 h. As control IgGs, we used IgGs purified from
normal rabbit serum or anti-FLAGM2 (Sigma-Aldrich) mouse monoclonal
antibody. Beads and inputs were treated with proteinase K overnight at 68°C
to degrade proteins and reverse cross-linking. Genomic DNA was finally
purified with Qiagen QIAquick PCR purification kit and eluted in 100 µl of
water.
The graphic representation of the CDKN1A locus and its chromatin
organization in human mammary epithelial cells was obtained from USCS
Genome browser (http://genome.ucsc.edu/). Analysis of the putative
binding site for MEF2D was performed using JASPAR ( jaspar.genereg.
net/).
Gene set enrichment analysis
Analyses were performed using the GSEA software (http://www.
broadinstitute.org/gsea/index.jsp). The list of MEF2 target genes was
obtained from theMolecular Signature Database (http://www.broadinstitute.
org/gsea/msigdb/index.jsp). The dataset for MCF10A cells was obtained
from GEO (http://www.ncbi.nlm.nih.gov/geo/) GSE26148 (Simpson et al.,
2011). Human normal and breast tumor samples were taken from
Curtis et al. (2012) with accession number EGAS00000000083,
deposited at the European Genome-Phenome Archive (EGA; http://www.
ebi.ac.uk/ega/).
Statistics
Results were expressed as the average±s.d. of at least three independent
experiments, except for ChIP experiments where the s.e.m. was calculated.
Results were expressed as the mean or median±s.d. of at least three
independent experiments, except for ChIP experiments where the s.e.m. was
calculated. Statistical analyses were performed using a Student’s t-test with
the level of significance set at P<0.05. Data from 3D acinar area
measurements were analyzed using the non-parametric Mann–Whitney
test (Prism GraphPad Software). Data were from at least three independent
experiments. *P<0.05; **P<0.01; ***P<0.005.
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